Podcasts about gmhc

Hear healthcare missionaries share their journeys. In the first hour hear a panel of two docs and two nurses answer your questions as well as: - How do I find God’s guidance in the journey? - Why and how do I connect with a mentor or agency or team or training? - What if my spouse or family are not supportive of me doing missions? The second hour will be small discussion group with a missionary coach and others like you in your current stage: - Exploring full-time missions - Heading towards full-time missions - Single or married One participant shared after one of these discussions, “I felt so overwhelmed at the size of GMHC. It was easy to feel lost in the crowd. In the Exploring small group discussion I was able to share my questions and fears.” Speaker(s): John McVay Session webpage: https://www.medicalmissions.com/events/gmhc-2024/sessions/exploring-the-journey-to-full-time-missions-agencies-funding-singlesfamilies-guidance

David Schachter was born on September 15, 1961 in Levittown, New York. David received a BFA in drama from NYU's Tisch School of the Arts in 1982. David worked extensively in Television, Off and Off-Off Broadway, and Regional Theater before landing the lead role of naive typesetter David Bennett in the groundbreaking indie drama Buddies (1985), which was the first theatrical film to address the devastating impact of the AIDS pandemic on the gay community in the 1980's. It was written, directed and produced by Aruthur Bressen Jr. the subject of today's podcast. David began volunteering at GMHC the Gay Men's Health Crisis in 1988 three years after the filming and release of Buddies. He was subsequently hired as a Community Organizer. David went on to earn his Master's Degree in public administration at the Robert F. Wagner Graduate School of Public Service in 1994. He began working at his alma mater NYU Wagner in the year 2000 and is now the Associate Dean of Student Affairs. He is a member of the school's senior leadership team and oversees the student experience including student advisement, student group activities, career services, and alumni relations. Today David joins  us to discuss the life and work of Arthur Bressen,Jr. Arthur Bressen, Jr. known to his friends as “Artie” was born  on May 27, 1943. He was an American director, writer, producer, documentarian, and gay pornographer, best known for pioneering independent queer cinema in the United States during the 1970s and 1980s. He wrote and directed the 1985 feature film Buddies, which was the first film to grapple with the subject of the AIDS pandemic. Other directorial endeavors include the largely influential 1977 documentary Gay USA (the first documentary by and about LGBTQ people), and the 1983 feature film Abuse. He died on July 29, 1987, at the age of 44 due to an AIDS-related illness.        

Recorded live on the beach and transferred from cassette tape

Recorded live on the beach and transferred from cassette tape

Recorded live on the beach and transferred from cassette tape

Recorded live on the beach and transferred from cassette tape

Recorded live on the beach and transferred from cassette tape

Underdogs often respond to systemic oppression through collective care – acts of mutual aid and cooperation with the goal of meeting people's basic survival needs when the state fails to do so. Some people feel collective care is just what we should do as decent human beings, but that it isn't a strategy for systemic social change. Others are more critical, noting that collective care can turn people away from strategies to change systems through organizing and political action. But when we (Stephanie and Deepak) taught our graduate class on Power & Strategy, one of our students, Walter Barrientos, an experienced organizer in the immigrant rights movement, argued that collective care is a strategy that movements have used effectively for centuries around the world. The more we read and discussed the topic, the more we became convinced, and we included collective care as the 7th of our “Seven Strategies to Change the World” in our book, Practical Radicals. In this episode, we look at collective care through the lens of the AIDS crisis and the remarkable work of the Gay Men's Health Crisis (GMHC). Our guest, Tim Sweeney joined and later ran that essential, underappreciated organization during some of the worst years when AIDS ravaged the LGBTQ+ community. After queer communities gained unprecedented visibility in the 1970s and early '80s, AIDS brought despair and decimation. (By 1995, one gay man in nine between the ages of twenty-five and forty-four in the United States had been diagnosed with AIDS, and nearly 7 percent had died. By comparison, COVID-19 has killed 0.3 percent of the U.S. population.) GMHC encouraged gay men and their allies to turn their grief and anger into action to help the sick and dying (with their buddy program), fight bigotry and misinformation (with their hotline and safer sex education projects), and advocate for better policies at every level of government. Although the better-known ACT UP is sometimes seen as a more radical alternative to GMHC, Tim explains that the two organizations actually complemented each other — with the care and community building of GMHC providing a ladder of engagement that helped foster self-confidence and led many to take part in ACT UP's headline-grabbing direct actions. In fact, as we discuss in the book, the first ACT UP meetings were co-facilitated by Tim Sweeney, and GMHC provided financial support to ACT UP at key points. We conclude that collective care done well is a strategy that can make all other strategies, such as base-building and disruption, more effective. When opportunities for systemic change seem to be foreclosed, collective care provides a path for people to achieve tangible change – and often discover new ways to achieve social transformation. Episode 10 transcript 

By 1986, almost 40 percent of people diagnosed with AIDS in the United States were either Black or Latino. As the full contours of the crisis became apparent, a group of Black gay men began to organize in cities across the country, demanding attention and support for the people dying in their midst. This effort required them to confront big, important institutions in both the medical establishment and the government — and it meant they had to stare down racism in the broader LGBTQ+ community. But perhaps their most pressing and consequential challenge was the most difficult to name: the rejection of their own community.As men, women and children within the Black community began falling ill, essential institutions — the family, the church, civil rights groups — which had long stood powerfully against the most brutal injustices, remained silent or, worse, turned away. Why? What made so many shrink back at such a powerful moment of need? And what would it take to get them to step up?In this episode, we meet some of the people who pushed their families, ministers and politicians to reckon with the crisis in their midst. We hear the words of a writer and poet, still echoing powerfully through the decades, demanding that he and his dying friends be both seen and heard; and we spend time with a woman who picked up their call, ultimately founding one of the country's first AIDS ministries. And we meet a legendary figure, Dr. Beny Primm, who, in spite of some of his own biases and blindspots, transformed into one of the era's leading medical advocates for Black people with HIV and AIDs. Along the way, we learn how one community was able to change — and we ask, what might have been different if that change had come sooner?Voices in the episode:• George Bellinger grew up in Queens, New York. He's been involved in activism since he was a teenager. He was an original board member of Gay Men of African Descent and also worked at GMHC and other HIV and AIDS organizations. He says his work is to “champion those who don't always have a champion.”• Gil Gerald is a Black HIV and AIDS activist and writer, who co-founded the National Coalition of Black Lesbians and Gays.• Cathy Cohen is the author of “The Boundaries of Blackness: AIDS and the Breakdown of Black Politics,” which is considered a definitive history of the epidemic in Black communities.• Governor David Paterson is the former governor of New York State and a former state senator. He is the son of Basil Paterson, who served as state senator from Harlem in the late 1960s, secretary of New York State in the 1980s, and was a longtime member of Harlem's political establishment.• Pernessa Seele is an immunologist and interfaith public health activist. She founded the Harlem Week of Prayer to End Aids and the Balm in Gilead.• Maxine Frere is a retired nurse who spent the entirety of her 40-year career at Harlem Hospital. A lifelong Harlem resident, she's been a member of First AME Church: Bethel since she was a kid.• Dr. Beny Primm was a nationally recognized expert on drug addiction and substance abuse treatment. His work on addiction led him to becoming one of the world's foremost experts on HIV and AIDS.• Lawrence Brown was Dr. Beny Primm's protégé who worked as an internist at Harlem Hospital and at Dr. Primm's Addiction Recovery and Treatment Center in Brooklyn. Brown served on the National Black Commission on AIDS, American Society of Addiction Medicine and took over for Dr. Primm as Director of ARTC (now START) when he retired.• Jeanine Primm-Jones is the daughter of Dr. Beny Primm, a pioneer of addiction treatment and recovery. Primm is a clinical social worker, abuse recovery specialist and wellness coach, who worked with her father for decades before his death in 2015.• Phill Wilson is the founder of the Black AIDS Institute, AIDS policy director for the city of Los Angeles at the height of the epidemic and a celebrated AIDS activist in both the LGBTQ+ and Black communities since the early 1980s.Audio from the 1986 American Public Health Association annual conference comes from APHA.Dr. Beny Primm archival audio comes from History Makers.This episode contains a brief mention of suicide. If you or someone you know is struggling with suicidal thoughts, there's help available. The National Suicide Prevention Lifeline is open 24 hours a day by calling or texting 988. There's also a live chat option on their website.Blindspot is a co-production of The HISTORY® Channel and WNYC Studios, in collaboration with The Nation Magazine.A companion photography exhibit by Kia LaBeija featuring portraits from the series is on view through March 11 at The Greene Space at WNYC. The photography for Blindspot was supported by a grant from the Economic Hardship Reporting Project, a nonprofit organization that promotes coverage of social inequality and economic justice.

Join this conversation with Ron Goldberg, the "chant queen" that inspired a movement, as we share the untold stories from the frontlines of AIDS activism. "Boy with the Bullhorn" isn't just a title; it's a testament to the relentless spirit of a community that refused to be silenced. From the origins of ACT UP's stirring chants to the raw emotional journey encapsulated in Ron's book, this episode is a deep exploration of how standing up and taking action can reshape the course of history. The power of activism takes center stage as we chart the transformative journey from grassroots care groups to the assertive strategies that aimed to wake America from its indifference to AIDS. Witness the rise of the "Silence = Death" campaign, the strategic protests that shook public consciousness, and the struggles within the broader queer rights movement. Through Ron's firsthand account, drawing from his award-winning book Boy witht the Bullhorn, we gain insight into the enduring legacy of these movements and the invaluable lessons they pass on to future generations fighting for equality and justice. And we reflect on the continuous impact of activism across decades.   The episode juxtaposes the hands-on defiance of the past with today's online advocacy, pondering how both methods forge societal change. Celebrating the resilience of the queer community, Ron Goldberg's narrative serves as a call to action—a reminder that our collective voices are not just necessary, but capable of conquering prejudice and securing the rights of all.  Recommended:The Boy with the Bullhorn - Ron Goldberg-------------------------Follow Deep Dive:InstagramPost.newsYouTube Email: deepdivewithshawn@gmail.com **Artwork: Dovi Design **Music: Joystock

Despite new FDA guidance lifting restrictions specific to gay/bisexual men donating blood, Jason Cianciotto of Gay Men's Health Crisis says public health messaging doesn't match practice. Jack O'Brien also interviews OUTBio's Ramsey Johnson on the role biopharma can play in supporting the LGBTQ+ community at work. And Elon Musk-backed Neuralink's move to human experimentation tops our Trends segment, along with items on Steven Tyler's vocal chords and TikTok's free-bleeding trend. Follow us: @MMMnewswww.mmm-online.com Music by  Sixième Son.

Welcome to our 3rd Year Anniversary special episode of the Breakfast With Tiffany Show podcast! In celebration of achieving another major milestone, we had the pleasure of inviting the charismatic Cecilia Gentili (She/Her), originally from Argentina but now living in the US as a proud transgender woman and advocate for the community. Join our inspiring talk with extraordinary stories and learn how Cecilia let life take her to unexpected places! Cecilia starts off by sharing her coming out story to her mom at 3 and a half years old knowing at the time that she was not a boy, then again at 17 as a transgendered person. Cecilia talks about how Argentina in the 70's was under a dictatorship where queer people were persecuted. With the lack of information, education, and a generation without the internet, Cecilia's first exposure to a transperson was in college at 17. We recognize how representation and exposure to identities can help guide people to feel seen and be authentic to who they are, as it did for Tiffany and Cecilia. Cecilia points out how sexuality and gender are consistent discoveries, as we don't fully know who we are until life takes us places we have never been to before. She adds how we shouldn't make plans for ourselves but rather embrace life and be open to it. The next question asks revolves around the secret to Cecilia's 8-year long loving relationship. She believes the secret is to be open to new experiences, not to take life too seriously, always find something to laugh together, and so on. She emphasizes the importance of maintaining joy and safety in your relationships. The discussion covers Cecilia's memoir as a survivor, healing from trauma,  recovering from substance abuse, and more. Lastly, Cecilia reminds us to respect each other's and our own version of beauty, happiness, and success.  ~~~Cecilia Gentili is an advocate, organizer, and storyteller working at the intersections of sex work, immigrant rights, incarceration issues, and trans liberation. She has years of experience in direct services and policy advocacy, working with organizations such as Apicha CHC, and GMHC; and as a founding member of both DecrimNY and Trans Equity Consulting. As a performer, Cecilia starred as Ms. Orlando in the hit FX Show Pose. She has also performed in her one-woman show The Knife Cuts Both Ways, and in countless storytelling events across the country. Cecilia's recently published epistolary memoir won the 2023 Stonewall Book Award. You can follow or contact Cecilia below; Twitter: @CeciliaGentili Instagram: @ceciliagentili72 Website: Trans Equity Consulting (Cecilia's company) ~ https://www.transequityconsulting.com/ Book: https://www.goodreads.com/book/show/61629767-faltas Support the showBreakfast With Tiffany Show Official Facebook Page ~ https://www.facebook.com/breakfastwithtiffanyshow Tiffany's Instagram Account ~ https://www.instagram.com/tiffanyrossdaleofficial/ For coaching sessions & programs with Tiffany, check out her official page ~ https://www.tiffanyrossdale.com Breakfast With Tiffany Show Youtube Channel ~ https://bit.ly/3vIVzhE Breakfast With Tiffany Show Official Page ~ https://www.tiffanyrossdale.com/podcast For questions, requests, collaborations and comments, feel free to reach us via our e-mail ~ breakfastwithtiffanyshow@outlook.com

Recorded live in the Pines. Transferred from audio cassette.

Javier Muñoz is an actor and activist whose impressive body of work spans theater, film and television. He is best known for starring and co-creating the role of "Alexander Hamilton'' in the hit musical HAMILTON on Broadway for two years after Lin-Manuel Miranda departed the show (and was his alternate prior to that). He got his break starring as “Usnavi” in IN THE HEIGHTS on Broadway, also created by Miranda. Javier starred in the dark comedy indie feature, MONUMENTS, opposite David Sullivan & Marguerite Moreau, the indie feature LOVE RECONSIDERED and stars in THREE MONTHS, opposite Troy Sivan and Judy Greer, on Paramount+. He voices a lead character in the Disney Jr. animated series, Eureka! Other TV credits include recurring role on Shadowhunters, Blindspot and Full Frontal with Samantha Bee. Javier is also an outspoken activist for LGBTQ+ rights, a Global Ambassador for (RED), which fights to end HIV/AIDS, and supporter of GMHC. Jessie Mueller is a Tony and Grammy Award-winning actress and singer. She was last seen on Broadway in Tracy Lett's The Minutes. Other recent credits include the Kennedy Center's Guys & Dolls, The Music Man, Julie Jordan in the Broadway revival of Rodgers and Hammerstein's Carousel (Tony & Grammy nominations, Drama Desk Award), originating the roles of both Jenna in Waitress (Tony, DD & Grammy noms) and Carole King in Beautiful-The Carole King Musical (Tony, Grammy & DD Awards.) Concert appearances include Carnegie Hall, Chicago's Lyric Opera, and Jazz at Lincoln Center. Film and Television: Steven Spielberg's The Post, Madam Secretary, Blue Bloods, Hulu's Candy, and Lifetime's Patsy & Loretta. She can be heard as part of the kooky cast of Netflix' Centaurworld and Wondery's Melon's House Party. New studio recordings include My Heart Says Go and Diary of A Wimpy Kid, The Musical. She is an Arts Education champion for groups such as Rosie's Theatre Kids (rosiestheaterkids.org) and a long-time supporter of The Entertainment Community Fund (entertainmentcommunity.org) & Broadway Cares Equity Fights Aids (broadwaycares.org). Learn more about your ad choices. Visit podcastchoices.com/adchoices

Recorded live in the Pines. Transferred from audio cassette.

Recorded live in the Pines. Transferred from audio cassette.

Recorded live in the Pines. Transferred from audio cassette.

Recorded live in the Pines. Transferred from audio cassette.

It is pride month, and we're spending intentional time this month – as we do every month – tracking movement for queer liberation and the legislative processes that try to muzzle the rights of our queer families. On today's show, our host Jesse Strauss visited the Berkeley Free Clinic to sit down with three volunteer members of the Gay Mens Health Collective – one of the many groups providing healthcare resources within the Clinic. The Gay Mens health collective was formed in the mid-70s to provide non-judgmental sexual health care to men in the context where the all-volunteer group providing those services were also men who had sex with men. This conversation is also personal. Our host, Jesse, spent time in the clinic as a kid while his dad volunteered in the clinic, and was a co-founder of the Gay Mens Health Collective almost 50 years ago. Our guests are GMHC volunteers Cam Breslin, Scott Carroll, and John Day. Check out the Berkeley Free Clinic website: https://www.berkeleyfreeclinic.org/ —- Subscribe to this podcast: https://plinkhq.com/i/1637968343?to=page Get in touch: lawanddisorder@kpfa.org Follow us on socials @LawAndDis: https://twitter.com/LawAndDis; https://www.instagram.com/lawanddis/ The post Visiting Berkeley's Gay Men's Health Collective w/ Cam Breslin, Scott Carroll, and John Day appeared first on KPFA.

Broadway star Javier Muñoz joins The Art of Kindness with Robert Peterpaul to kick off Pride month and reflect on: acts of kindness in Hamilton, working on the new musical album My Heart Says Go alongside Jessie Mueller, making theatre accessible, self-acceptance and much more. Javier Muñoz is an actor and activist whose impressive body of work spans theater, film and television. He is best known for starring and co-creating the role of "Alexander Hamilton'' in the hit musical HAMILTON on Broadway for two years after Lin-Manuel Miranda departed the show (and was his alternate prior to that). He got his break starring as “Usnavi” in IN THE HEIGHTS on Broadway, also created by Miranda. Javier starred in the dark comedy indie feature, MONUMENTS, opposite David Sullivan & Marguerite Moreau, the indie feature LOVE RECONSIDERED and stars in THREE MONTHS, opposite Troy Sivan and Judy Greer, on Paramount+. He voices a lead character in the Disney Jr. animated series, Eureka! Other TV credits include recurring role on Shadowhunters, Blindspot and Full Frontal with Samantha Bee. Javier is also an outspoken activist for LGBTQ+ rights, a Global Ambassador for (RED), which fights to end HIV/AIDS, and supporter of GMHC. Got kindness tips or stories? Please email us: artofkindnesspodcast@gmail.com Follow Javier @javiermofficial Follow us @artofkindnesspod / @robpeterpaul Support the show! (https://www.buymeacoffee.com/theaok) Music: "Awake" by Ricky Alvarez & "Sunshine" by Lemon Music Studio. We are supported by the Broadway Podcast Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

Hear healthcare missionaries share their journeys. In the first hour hear a panel of two docs and two nurses answer your questions as well as: How do I find God’s guidance in the journey? Why and How do I connect with a mentor, agency, team, and/or training? What about student loans, and raising financial support? What if my spouse or family are not supportive of me doing missions? The second hour will be small discussion group with a missionary coach and others like you in your current stage: Exploring whether or not to consider full-time missions Heading towards full-time missions Single or married Here are some comments from a previous GMHC: “My group leader was great and answered a lot of the questions that I had.” “My leader did a great job being open and honest about her experiences.”

Analisa Packham talks about the effects of syringe exchange programs on HIV rates, opioid abuse, and crime. This episode was first posted in May 2019. "Are Syringe Exchange Programs Helpful or Harmful? New Evidence in the Wake of the Opioid Epidemic" by Analisa Packham. *** Probable Causation is part of Doleac Initiatives, a 501(c)(3) nonprofit. If you enjoy the show, please consider making a tax-deductible contribution. Thank you for supporting our work! *** OTHER RESEARCH WE DISCUSS IN THIS EPISODE: “Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS among injecting drug users” — World Health Organization report. “Needle exchange programs and drug injection behavior” by Jeff DeSimone. “Needle exchange programs: Research suggests promise as an AIDS prevention strategy” — GAO report. “Syringe exchange programs around the world: The global context” — GMHC report. “The Effects of Naloxone Access Laws on Opioid Abuse, Mortality, and Crime” by Jennifer L. Doleac and Anita Mukherjee

In this special video interview, community leader in resident Jade Elektra stops by the lab to share updates on her community work and chat about her iconic career.   Jade Elektra is a Toronto-based "out" HIV+ Queer African-American Drag Entertainer, Recording Artist/Live Singer, Film/Stage/Television Actor and AIDS Activist originally from Tampa, Florida via New York City and finally found a home in Toronto in 2010. After being diagnosed in 1990 (but infected in 1989) Jade dreamed of leaving Tampa, Florida for hustle and bustle of New York City. With a little money saved and the kindness of a queen called “The Electrifying Grace” Jade came to The Big Apple in 1992. She started auditioning and getting small parts but Jade's recording career was born out of this time. Jade also formed a drag revue called “The Illusions” (Harmonica Sunbeam, Sybil Barrington, Tyra Colbaire & Victoria Lace). The revue became the only drag show in Harlem in the 90s. It's finale ended at The Apollo in 1995. Probably best known at first for her underground club hits like “Why Are You Gaggin'?” and “Bitch You Look Fierce”, these became staples of the NYC Ballroom Community. Jade found herself in the company of cast members of “Paris Is Burning” as they took her into the scene. Jade worked out of drag at Sally's II as the DJ and would later be named DJ Relentless. Pepper LaBeija was her House Mother. Paris Dupree was her upstairs neighbour. Octavia St. Laurent, Angie Xtravaganza and Dorian Corey were the showgirls at Sally's. The 90s were a great time for drag and film. Jade was in “Too Wong Foo. Thanks For Everything, Julie Newmar.” “Party Girl” “Stonewall” and “Jane Doe”. And daytime television seemed to like Jade as well. 2 episodes of Ricky Lake, 1 episode of Maury Povich and 13 episodes of The Richard Bey Show. In 1998, Jade performed at Wigstock with her debut single "Why Are You Gagging?" on Progressive High Records ( a division of Atlantic Records).     By the year 2000, Jade had been approached by Andrew Neville in the UK about producing an album. The idea was to have Jade be the UK version of RuPaul. The album was recorded and promotion were being set in place. The record label's offices were in the Twin Towers. 9/11 happened and everything ended. NYC took many years to recover and lost many of its creative and nightlife scene. In the years after 9/11, Jade found herself volunteering at GMHC and The Harvey Milk School. It was these years when she realized the importance of educating our youth about HIV/AIDS. She was not completely out about her status except for close friends and lovers. But that was all about to change in 2005 when she met artist, John Richard Allan. A long distance romance blossomed and Allan proposing on World AIDS Day 2009. Jade relocated to Toronto and officially came out in Fab Magazine in 2010. John Allan had already created POZPLANET the facebook group. So, Jade created POZ-TO, a monthly social gathering for the HIV+ Community. This grew into the POZ-TO Awards where each year we began honouring ten unsung heroes of HIV/AIDS. Over the 2010s decade Jade found herself speaking out for many causes but it would be the opportunity to be the first drag queen to sing at The AIDS Memorial at The 519 in 2019 that would end up going viral. A slight change of “Unforgettable” to “Undetectable” spoke for many living with HIV and knowing that as long as long as they were undetectable they were untransmittable. U=U Today Jade is resident at the University of Toronto for their Queer & Trans Research Lab. Her latest album dropped on November 2nd, 2022 called "Legendary, Darling!" ( a collection of her early tracks to her most current on iUnderground Records. And as far as her discography, Jade Elektra has a list of music that covers 1997 to current playlists today on iTunes, Spotify and YouTube.

DESCRIPTION- This week the Angel Of Words podcast gets a special heartfelt performance from poet Rob Vassilarakis @simply_rob_vassilarakis who performs his poem "7 Years" about his bout with HIV/AIDS. He also discusses the terrible messaging from the mainstream media during the beginning stages of the monkeypox outbreak. Plus we get into his work with the AIDS organization GMHC , and he opens up about living with HIV, and analyzes the treatments available to survivors such as PREP and PEP. We get deep on this one! so stay locked here “Where your stories are heard”. THE BREAKDOWN- MIN- 0:00- INTRODUCTION MIN- 3:02 - THE TRUTH ABOUT MONKEYPOX. IS THE MAINSTREAM MEDIA TELLING THE TRUTH ABOUT MONKEYPOX? IS MONKEYPOX MORE PREVALENT IN LGBTQ COMMUNITIES? HOW TO PROTECT YOURSELF AGAINST MONKEYPOX. MIN- 10:28- WHAT IS THE GMHC (GAY MEN'S HEALTH CRISIS). WHAT DOES THE GMHC DO FOR THE LGBTQ COMMUNITIES? ROB'S ROLE WITHIN THE GMHC. HOW TO STOP THE SPREAD OF MONKEYPOX, HIV, AND AIDS WITHIN THE LGBTQ COMMUNITIES. MIN 20:37- THE HIV AND AIDS SITUATION RIGHT NOW,. WHAT IS PREP? WHAT IS PEP? PREP VS PEP? THE PEP HOTLINE NUMBER 844-373-7692. HOW TO PREVENT HIV AND AIDS RIGHT NOW? MIN- 32:04- HOW ROB BECAME A POET? BEST POET IN NYC. WHO IS LA BRUJA? HIS RELATIONSHIP WITH LA BRUJA AND THE NUYORICAN POET CAFE. MIN 46:03- 5 WORDS WITH ANGEL (GAME SHOW SEGMENT) MIN 52;35- LIVE PERFORMANCE OF "7 YEARS' A POEM BY ROB VASSILARAKIS. THESE PRODUCTS CAN BE USED TO START A PODCAST OF YOUR OWN; (DESCRIPTION AND BREAKDOWN OF EPISODE BELOW). RODE Pod-MIC- https://amzn.to/3s7QjCGXLR Cables- https://amzn.to/3ueK8iMRODECaster Pro- https://amzn.to/3gdoeV6Behringer Headphones- https://amzn.to/3KY0nqI Ameriwood Home Parsons Desk with Drawer, Black- https://amzn.to/3rdl6Pc

Hear healthcare missionaries share their journeys. In the first hour hear a panel of two docs and two nurses answer your questions as well as: How do I find God’s guidance in the journey? Why and how do I connect with a mentor or agency or team or training? What about student loans, raising financial support? What if my spouse or family are not supportive of me doing missions? The second hour will be small discussion group with a missionary coach and others like you in your current stage: Exploring whether or not to consider full-time missions Heading towards full-time missions Single or married Here are some comments from a previous GMHC: “My group leader was great and answered a lot of the questions that I had.” “My leader did a great job being open and honest about her experiences.”

This special outtake from "TIM" is a nod to the GMHC (The Gay Men's Health Crisis), the world's first HIV/AIDS service organization.  Since 1981, the GMHC has been working to end the AIDS epidemic and uplift the lives of all affected.  "TIM" is an original two-part monologue from author/performer/activist Abby Stokes.  She shares her intimate story of love and loss during the early '90s AIDS crisis in New York City.  Listen and subscribe to TIM wherever you get your podcasts or live & direct on jasoncharles.net Podcast Network Audio Dramas Channel In this outtake from the main monologue featured in Parts 1 and 2, Abby reveals candid memories of her time at the GMHC with an amazing group of people who shared the experience of caring for and ultimately losing someone they love.  She shares her experience during Tim's hospitalization when he made her promise to get some help for while she was spending most of her time helping him, which she ultimately did thanks to the GMHC. For more information about Abby Stokes go to www.abbystokes.com For more information about the GMHC, go to GMHC.ORG   See omnystudio.com/listener for privacy information.

It's the final episode of our first season (sob), and there is no better artist, soul, human to help us close it out than Michael Urie. We talk about the crazy time we all find ourselves in, the value - and the work - of real self care, how to pay attention to the signals we are given, and how our understanding of spirituality has evolved individually and over the course of this podcast. A self-proclaimed agnostic, Michael never thought he'd be invited to the show (even though he's our hashtag number one listener), so we were thrilled to go deep, share some laughs, and sit in the warm glow of his charisma. As an actor, Michael is most well known for his television work as Marc St. James on Ugly Betty, Gavin Sinclair on Modern Family, Redmond on Younger, roles on Partners, Workaholics, Hot in Cleveland, The Good Wife, and The Good Fight. Movies include: Single All The Way, Swan Song, The Decoy Bride, Petunia, Beverly Hills Chihuahua, Lavender, the upcoming Jersey Boys Live starring Nick Jonas. On Broadway, Michael has appeared in Douglas Lyons' Chicken & Biscuits, Bess Wohl's Grand Horizons, Harvey Fierstein's Torch Song and How To Succeed in Business Without Really Trying. Off Broadway, on tour and in London, he did more than 600 performances of Jonathan Tolins' solo play Buyer & Cellar - including one from his living room early in the pandemic streamed live on Broadway.com, raising nearly 300k for Broadway Care Equity Fights Aids. Other Off Broadway plays include Jane Anger, The Temperamentals, The Government Inspector, Homos or Everyone in America, Shows for Days, High Button Shoes, The Cherry Orchard, and two Tony Kushner plays: A Bright Room Called Day and Angels in America. Behind the scenes, Michael directed Bright Colors and Bold Patterns and produced Happy Birthday Doug (both plays written and performed by Drew Droege and both available on BroadwayHD), directed the short film The Hyperglot, feature comedy film He's Way More Famous Than You and co-directed Thank You For Judging an award winning documentary about High School speech tournaments. He's narrated the audiobooks Lily And The Octopus, Hero, Midnight Cowboy and The Editor. He is the recipient of two Drama Desk Awards, two Lucille Lortel Awards, an Obie, an LA Drama Critics Award, Actors Equity's Clarence Derwent award, as well as GMHC's Howard Ashman Award, The Broadway Beacon Award, Coach Art's Coach Champion Award and Juilliard's John Houseman Award. He lives in New York with his partner Ryan and their children, a dog and cat. Follow Michael: On IG: @michaelurielikesit On Twitter: @michaelurie This week's Do: Support Equality Florida - https://www.eqfl.org/   Follow us! On IG: @art.fully.grounded On FB: @art.fully.grounded On Twitter: @AFGpod Podcast's website: www.sweptbythewind.com/podcast 

In this special episode of Vax On, Matthew Zachary and Elura Nanos talk with Ms. Information and Krishna Stone from Gay Men's Health Crisis, the world's first HIV/AIDS service organization. They Discuss Ms. Information's unique approach to busting myths and how the LGBTQ community has been affected by COVID-19.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

An exceptional Photographer, Creative Director and Visual Storyteller known for his signature style with Beauty, Celebrity & Fashion Photography. His list of clients include Cardi B, Billy Porter, Priyanka Chopra, Lewis Hamilton, Ruby Rose, Kim Kardashian, Katy Perry, Prince, Taraji P. Henson, Jim Parsons, Queen Latifah, Betty White & Kelly Clarkson. He has gone on to direct music videos for Kelly Rowland, Vanessa Williams & Erika Jayne. Mike made his feature film directorial debut with RuPaul's uproarious comedy Starrbooty. He was recently named creative director and principal photographer for L'Officiel Fashion Book Australia, L'Officiel Fashion Book Monte Carlo and PhotoBook Magazine. Mike supports the Ali Forney Center, GMHC, The Trevor Project, Housing Works, It Gets Better Project, Live Out Loud, Project Angel Food, Stand Up for Pits Foundation and GLAAD. He serves on the honorary board of the “Let There Be Hope” research foundation. On this episode he shares what it was like shooting with Prince at Paisley Park, he explains his rich fantasy life as a kid and how the discovery of his first camera allowed him to express his vision of the world. To learn more go to MikeRuiz.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Bio for Anthony Hayes Anthony Hayes is President and Founder of The Hayes Initiative (THI) and has spent more than 18 years in communications, crisis and issue management, and political and legislative campaigns. Episode highlightListen in on how Anthony Hayes developed a niche in extreme crisis management by applying his own personal discretion to sensitive national and international crises. LinksEmail: Anthony@hayesinitiative.com Website: https://hayesinitiative.comLinkedIn: https://www.linkedin.com/in/anthonyjhayesnyc/Quotes“It was certainly a place of extreme torment because what was coming through from the pope was hellfire and brimstone and especially words like abomination if you are gay aren't really the best things to… wrestle with.”“A lot of New Yorkers don't understand that the rest of the world doesn't live the way we live and have all the privileges and things we have.”TakeawaysChildhood IncidentsAnthony grew up in Enid, Oklahoma at a time when he couldn't talk about having a crush on his male classmate. He claims that he became skilled at storytelling in order to distract the people in his life from his truth.Despite being funny and popular in school, Anthony turned to alcohol and cigarettes to numb his pain at age 13 and went to rehab at 16. He drank again between the ages of 18 and 30, but has been sober ever since. Influential Groups Anthony learned a strong work ethic from his parents, who were also part of the Church of Christ, where “being gay” was not allowed. Anthony developed insight, vulnerability, and camaraderie at Alcoholics Anonymous.Moving to New York City in his 20s helped him become an active part of advocacy groups like GMHC, an AIDS-service organization of which he is proud to be a part. Temperament and Personality InfluencesLooking back on his life, Anthony describes himself as optimistic. As an adult, he focuses on being aware of the present moment and living with wisdom. Cultural EpiphaniesBeing a New Yorker, Anthony understands that the city can be a bubble of lived experience and political opinion, making residents oblivious to differences outside of it. Advice to an Employer Anthony enjoys working with clients who respect his expertise and are willing to be vulnerable and transparent about the gaps that he needs to fill. More Great Insights! Reach out to Anthony on LinkedIn or through his website to connect! Support the show (https://www.patreon.com/cultureandleadershipconnections)

Sins Of Omission: The AZT Scandal By Celia Farber Spin Nov. 1989 On a cold January day in 1987, inside one of the brightly-lit meeting rooms of the monstrous FDA building, a panel of 11 top Aids doctors pondered a very difficult decision. They had been asked by the FDA to consider giving lightning-quick approval to a highly toxic drug about which there was very little information. Clinically called Zidovudine, but nicknamed AZT after its components, the drug was said to have shown a dramatic effect on the survival of Aids patients. The study that had brought the panel together had set the medical community abuzz. It was the first flicker of hope - people were dying much faster on the placebo than on the drug.  But there were tremendous concerns about the new drug. It had actually been developed a quarter of a century earlier as a cancer chemotherapy, but was shelved and forgotten because it was so toxic, very expensive to produce, and totally ineffective against cancer. Powerful, but unspecific, the drug was not selective in its cell destruction.  Drug companies around the world were sifting through hundreds of compounds in the race to find a cure, or at least a treatment, for Aids. Burroughs Wellcome, a subsidiary of Wellcome, a British drug company, emerged as the winner. By chance, they sent the failed cancer drug, then known as Compound S, to the National Cancer Institute along with many others to see if it could slay the Aids dragon, HIV. In the test tube at least, it did.  At the meeting, there was a lot of uncertainty and discomfort with AZT. The doctors who had been consulted knew that the study was flawed and that the long-range effects were completely unknown. But the public was almost literally baying at the door. Understandably, there was immense pressure on the FDA to approve AZT even more quickly than they had approved thalidomide in the mid-60s, which ended up causing drastic birth defects.  Everybody was worried about this one. To approve it, said Ellen Cooper, an FDA director, would represent a "significant and potentially dangerous departure from our normal toxicology requirements."  Just before approving the drug, one doctor on the panel, Calvin Kunin, summed up their dilemma. "On the one hand," he said, "to deny a drug which decreases mortality in a population such as this would be inappropriate. On the other hand, to use this drug widely, for areas where efficacy has not been demonstrated, with a potentially toxic agent, might be disastrous."  "We do not know what will happen a year from now," said panel chairman Dr. Itzhak Brook. "The data is just too premature, and the statistics are not really well done. The drug could actually be detrimental." A little later, he said he was also "struck by the facts that AZT does not stop deaths. Even those who were switched to AZT still kept dying."  "I agree with you," answered another panel member, "There are so many unknowns. Once a drug is approved there is no telling how it could be abused. There's no going back."  Burroughs Wellcome reassured the panel that they would provide detailed two-year follow-up data, and that they would not let the drug get out of its intended parameters: as a stopgap measure for very sick patients.  Dr. Brook was not won over by the promise. "If we approve it today, there will not be much data. There will be a promise of data," he predicted, "but then the production of data will be hampered." Brook's vote was the only one cast against approval.  'There was not enough data, not enough follow-up," Brook recalls. "Many of the questions we asked the company were answered by, 'We have not analyzed the data yet,' or 'We do not know.' I felt that there was some promising data, but I was very worried about the price being paid for it. The side effects were so very severe. It was chemotherapy. Patients were going to need blood transfusions. That's very serious.  "The committee was tending to agree with me," says Brook, "that we should wait a little bit, be more cautious. But once the FDA realized we were intending to reject it, they applied political pressure. At about 4 p.m., the head of the FDA's Center for Drugs and Biologics asked permission to speak, which is extremely unusual. Usually they leave us alone. But he said to us, 'Look, if you approve the drug, we can assure you that we will work together with Burroughs Wellcome and make sure the drug is given to the right people.' It was like saying 'please do it.'"  Brad Stone, FDA press officer, was at that meeting. He says he doesn't recall that particular speech, but that there is nothing 'unusual" about FDA officials making such speeches at advisory meetings. "The people in that meeting approved the drug because the data the company had produced proved it was prolonging life. Sure it was toxic, but they concluded that the benefits clearly outweighed the risks."  The meeting ended. AZT, which several members of the panel still felt uncomfortable with and feared could be a time bomb, was approved.  Flash forward: August 17, 1989. Newspapers across America banner-headlined that AZT had been "proven to be effective in HIV antibody-positive, asymptomatic and early ARC patients," even through one of the panel's main concerns was that the drug should only be used in a last-case scenario for critically-ill AIDS patients, due to the drug's extreme toxicity. Dr. Anthony Fauci, head of the National Institutes of Health (NIH), was now pushing to expand prescription.  The FDA's traditional concern had been thrown to the wind. Already the drug had spread to 60 countries and an estimated 20.000 people. Not only had no new evidence allayed the initial concerns of the panel, but the follow-up data, as Dr. Brook predicted, had fallen by the waysite. The beneficial effects of the drug had been proven to be temporary. The toxicity, however stayed the same.  The majority of those in the AIDS afflicted and medical communities held the drug up as the first breakthrough on AIDS. For better or worse, AZT had been approved faster than any drug in FDA history, and activists considered it a victory. The price paid for the victory, however, was that almost all government drug trials, from then on, focused on AZT - while over 100 other promising drugs were left uninvestigated.  Burroughs Wellcome stock went through the roof when the announcement was made. At a price of $8,000 per patient per year (not including blood work and transfusions), AZT is the most expensive drug ever marketed. Burroughs Wellcome's gross profits for next year are estimated at $230 million. Stock market analysts predict that Burroughs Wellcome may be selling as much as $2 billion worth of AZT, under the brand name Retrovir, each year by the mid-1990s - matching Burroughs Wellcome's total sales for all its products last year.  AZT is the only antiretroviral drug that has received FDA approval for treatment of AIDS since the epidemic began 10 years ago, and the decision to approve it was based on a single study that has long been declared invalid.  The study was intended to be a "double-blind placebo-controlled study," the only kind of study that can effectively prove whether or not a drug works. In such a study, neither patient nor doctor is supposed to know if the patient is getting the drug or a placebo. In the case of AZT, the study became unblinded on all sides, after just a few weeks.  Both sides of the contributed to the unblinding. It became obvious to doctors who was getting what because AZT causes such severe side effects that AIDS per se does not. Furthermore, a routine blood count known as CMV, which clearly shows who is on the drug and who is not, wasn't whited out in the reports. Both of these facts were accepted and confirmed by both the FDA and Burroughs Wellcome, who conducted the study.  Many of the patients who were in the trial admitted that they had analyzed their capsules to find out whether they were getting the drug. If they weren't, some bought the drug on the underground market. Also, the pills were supposed to be indistinguishable by taste, but they were not. Although this was corrected early on, the damage was already done. There were also reports that patients were pooling pills out solidarity to each other. The study was so severely flawed that its conclusions must be considered, by the most basic scientific standards, unproven.  The most serious problem with the original study, however, is that it was never completed. Seventeen weeks in the study, when more patients had died in the placebo group, the study was stopped short, and all subjects were put on AZT, no scientific study can ever be conducted to prove unequivocally whether AZT does prolong life.  Dr. Brook, who voted against approval, warned at the time that AZT, being the only drug available for doctors to prescribe to AIDS patients, would probably have a runaway effect. Approving it prematurely, he said, would be like "letting the genie out of the bottle."  Brook pointed out that since the drug is a form of chemotherapy, it should only be prescribed by doctors who have experience with chemotherapeutic drugs. Because of the most severe toxic effects of AZT - cell depletion of the bone marrow - patients would need frequent blood transfusions. As it happened, AZT was rampantly prescribed as soon as it was released, way beyond its purported parameters. The worst-case scenario had come true: Doctors interviewed by the New York Times later in 1987 revealed that they were already giving AZT to healthy people who had tested positive for antibodies to HIV.  The FDA's function is to weigh a drug's efficacy against its potential hazards. The equation is simple and obvious: A drug must unquestionably repair more than it damages, otherwise the drug itself may cause more harm than the disease it is supposed to fight. Exactly what many doctors and scientists fear is happening with AZT.  AZT was singled out among hundreds of compounds when Dr. Sam Broder, the head of the National Cancer Institutes (NCI), found that it "inhibited HIV viral replication in vitro." AIDS is considered a condition of immune suppression caused by the HIV virus replicating and eating its way into T-4 cells, which are essential to the immune system. HIV is a retrovirus which contains an enzyme called reverse transcriptase that converts viral RNA to DNA. AZT was thought to work by interrupting this DNA synthesis, thus stopping further replication of the virus.  While it was always known that the drug was exceedingly toxic, the first study concluded that 'the risk/benefits ratio was in favour of the patient."  In the study that won FDA approval for AZT, the one fact that swayed the panel of judges was that the AZT group outlived the placebo group by what appeared to be a landslide. The ace card of the study, the one that cancelled out the issue of the drug's enormous toxicity, was that 19 persons had died in the placebo group and only one in the AZT group. The AZT recipients were also showing a lower incidence of opportunistic infections.  While the data staggered the panel that approved the drug, other scientists insisted that it meant nothing - because it was so shabbily gathered, and because of the unblinding. Shortly after the study was stopped, the death rate accelerated in the AZT group. "There was no great difference after a while," says Dr. Brook, "between the treated and the untreated group."  "That study was so sloppily done that it really didn't mean much," says Dr. Joseph Sonnabend, a leading New York City AIDS doctor.  Dr. Harvey Bialy, scientific editor of the journal Biotechnology, is stunned by the low quality of science surrounding AIDS research. When asked if he had seen any evidence of the claims made for AZT, that it "prolongs life" in AIDS patients, Bialy said, "No. I have not seen a published study that is rigorously done, analyzed and objectively reported."  Bialy, who is also a molecular biologist, is horrified by the widespread use of AZT, not just because it is toxic, but because, he insists, the claims its widespread use are based upon are false. "I can't see how this drug could be doing anything other than making people very sick," he says.  The scientific facts about AZT and AIDS are indeed astonishing. Most ironically, the drug has been found to accelerate the very process it was said to prevent: the loss of T-4 cells.  "Undeniably, AZT kills T-4 cells [white blood cells vital to the immune system]" says Bialy. "No one can argue with that. AZT is a chain-terminating nucleotide, which means that it stops DNA replication. It seeks out any cell that is engaged in DNA replication and kills it. The place where most of this replication is taking place is the bone marrow. That's why the most common and severe side effect of the drug is bone marrow toxicity. That is why they [patients] need blood transfusions."  AZT has been aggressively and repeatedly marketed as a drug that prolongs survival in AIDS patients because it stops the HIV virus from replicating and spreading to healthy cells. But, says Bialy: "There is no good evidence that HIV actively replicates in a person with AIDS, and if there's isn't much HIV replication in a person with AIDS, and if there isn't much HIV replication to stop, it's mostly killing healthy cells."  University of California at Berkeley scientist Dr. Peter Duesberg drew the same conclusion in a paper published in the Proceedings, the journal of the National Academy of Sciences. Duesberg, whose paper addressed his contention that HIV is not a sufficient cause for AIDS, wrote: "Even if HIV were to cause AIDS, it would hardly be legitimate target for AZT therapy, because in 70 to 100 percent of antibody positive persons, proviral DNA is not detectable... and its biosynthesis has never been observed."  As a chemotherapeutic drug, explained Duesberg, explained Duesberg, AZT "kills dividing blood cells and other cells," and is thus "directly immunosuppressive."  "The cell is almost a million-fold bigger target than the virus, so the cell will be much, much more sensitive," says Duesberg. "Only very few cells, about one in 10,000 are actively making the virus containing DNA, so you must kill incredibly large numbers of cells to inhibit the virus. This kind of treatment could only theoretically help if you have a massive infection, which is not the case with AIDS. Meanwhile, they're giving this drug that ends up killing millions of lymphocytes [white blood cells]. It's beyond me how that could possibly be beneficial."  "It doesn't really kill them," Burroughs Wellcome scientists Sandra Lehrman argues. "You don't necessarily have to destroy the cell, you can just change the function of it. Furthermore, while the early data said that the only very few cells were infected, new data says that there may be more cells infected. We have more sensitive detection techniques now."  "Changes their function? From what - functioning to not functioning? Another example of mediocre science," says Bialy. "The 'sensitive detection technique' to which Dr. Lehrman refers, PCR, is a notoriously unreliable one upon which to base quantitative conclusions."  When specific questions about the alleged mechanisms of AZT are asked, the answers are long, contradictory, and riddled with unknowns. Every scientific point raised about the drug is eventually answered with the blanket response, "The drug is not perfect, but it's all we have right now." About the depletion of T-4 cells and other white cells, Lehrman says, "We don't know why T-4 cells go up at first, and then go down. That is one of the drug mechanisms that we are trying to understand."  When promoters of AZT are pressed on key scientific points, whether at the NIH, FDA, Burroughs Wellcome or an AIDS organization, they often become angry. The idea that the drug is "doing something," even though this is invariably followed with irritable admissions that there are "mechanisms about the drug and disease we don't understand," is desperately clung to. It is as if, in the eye of the AIDS storm, the official, government-agency sanctioned position is immunized against critique. Skepticism and challenge, so essential to scientific endeavour, is not welcome in the AZT debate, where it is arguably needed more than anywhere else.  The toxic effects of AZT, particularly bone marrow suppression and anemia, are so severe that up to 50 percent of all AIDS and ARC patients cannot tolerate it and have to be taken off it. In the approval letter that Burroughs Wellcome sent to the FDA, all of 50 additional side effects of AZT, aside from the most common ones, were listed. These included: loss of mental acuity, muscle spasms, rectal bleeding and tremors.  Anemia one of AZT's common side effects, is the depletion of red blood cells, and according to Duesberg, "Red blood cells are the one thing you cannot do without. Without red cells, you cannot pick up oxygen."  Fred, a person with AIDS, was put on AZT and suffered such severe anemia from the drug he had to be taken off it. In an interview in the AIDS handbook Surviving and Thriving With AIDS, he described what anemia feels like to the editor Michael Callen: "I live in a studio and my bathroom is a mere five-step walk from my be. I would just lie there for two hours; I couldn't get up to take those five steps. When I was taken to the hospital, I had to have someone come over to dress me. It's that kind of severe fatigue... The quality of my life was pitiful... I've never felt so bad... I stopped the AZT and the mental confusion, the headaches, the pains in the neck, the nausea, all disappeared within a 24-hour period."  "I feel very good at this point," Fred went on. "I feel like the quality of my life was a disaster two weeks ago. And it really was causing a great amount of fear in me, to the point where I was taking sleeping pills to calm down. I was so worried. I would totally lose track of what I was saying in the middle of a sentence. I would lose my directions on the street."  "Many AIDS patients are anemic even before they receive the drug." Says Burroughs Wellcome's Dr. Lehrman, "because HIV itself can infect the bone marrow and cause anemia."  This argument betrays a bizarre reasoning. If AIDS patients are already burdened with the problems such as immune suppression, bone marrow toxicity and anemia, is compounding these problems an improvement?  "Yes AZT is a form of chemotherapy." Says the man who invented the compound a quarter-century ago, Jerome Horowitz. "It is cytotoxic, and as such, it causes bone marrow toxicity and anemia. There are problems with the drug. It's not perfect. But I don't think anybody would agree that AZT is of no use. People can holler from now until doomsday that it is toxic, but you have to go with the results."  The results, finally and ironically, are what damns AZT. Several studies on the clinical effects of AZT - including the one that Burroughs Wellcome's approval was based on - have drawn the same conclusion: that AZT is effective for a few months, but that its effect drops of sharply after that. Even the original AZT study showed that T-4 cells went up for a while and then plummeted. HIV levels went down, and then came back up. This fact was well-known when the advisory panel voted for approval. As panel member Dr. Stanley Lemon said in the meeting, "I am left with the nagging thought after seeing several of these slides, that after 16 to 24 weeks - 12 to 16 weeks, I guess - the effect seems to be declining."  A follow-up meeting, two years after the original Burroughs Wellcome study, was scheduled to discuss the long range effects of AZT, and the survival statistics. As one doctor present at that meeting in May 1988 recall, "They hadn't followed up the study. Anything that looked beneficial was gone within half a year. All they had were some survival statistics averaging 44 weeks. The p24 didn't pan out and there was no persistent improvement in the T-4 cells."  HIV levels in the blood are measured by an antigen called p24. Burroughs Wellcome made the claim that AZT lowered this level, that is, lowered the amount of HIV in the blood. At the first FDA meeting, Burroughs Wellcome emphasized how the drug had "lowered" the p24 levels; at the follow-up meeting, they didn't mention it.  As that meeting was winding down, Dr. Michael Lange, head of the AIDS program at St. Luke's-Roosevelt Hospital in New York, spoke up about this. "The claim of AZT is made on the fact that it is supposed to have an antiviral effect," he said to Burroughs Wellcome, "and on this we have seen no data at all... Since there is a report in the Lancet [a leading British medical journal] that after 20 weeks or so, in many patients p24 came back, do you have any data on that?"  They didn't.  "What counts is the bottom line," one of the scientists representing Burroughs Wellcome summed up, "the survival, the neurologic function, the absence of progression and the quality of life, all of which are better. Whether you call it better because of some antiviral effect, or some other antibacterial effect, they are still better."  Dr. Lange suggested that the drug may be effective the same way a simple anti-inflammatory, such as aspirin, is effective. An inexpensive, nontoxic drug called Indomecithin, he pointed out, might serve the same function, without the devastating side effects.  One leading AIDS researcher, who was part of the FDA approval process, says today: "Does AZT do anything? Yes, it does. But the evidence that it does something against HIV is really not there."  "There have always been drugs that we use without knowing exactly how they work," says Nobel Prize winner Walter Gilbert. "The really important thing to look at is the clinical effect. Is the drug helping or isn't it?"  "I'm living proof that AZT works," says one person with ARC on AZT. "I've been on it for two years now, and I'm certainly healthier than I was two years ago. It's not a cure-all, it's not a perfect drug, but it is effective. It's slowing down the progression of the disease."  "Sometimes I feel like swallowing Drano," says another. "I mean, sometimes I have problems swallowing. I just don't like the idea of taking something that foreign to my body. But every six hours, I've got to swallow it. Until something better comes along, this is what is available to me."  "I am absolutely convinced that people enjoy a better quality of life and survive longer who do not take AZT," says Gene Fedorko, President of Health Education AIDS Liaison (HEAL). "I think it's horrible the way people are bullied by their doctors to take the drug. We get people coming to us shaking and crying because their doctors said they'll die if they don't take AZT. That is an absolute lie." Fedorko has drawn his conclusion from years of listening to the stories of people struggling to survive AIDS at HEAL's weekly support group.  "I wouldn't take AZT if you paid me," says Michael Callen, cofounder of New York City's PWA coalition, Community Research Initiative, and editor of several AIDS journals. Callen has survived AIDS for over seven years without the help of AZT. "I've gotten the shit kicked out me for saying this, but I think using AZT is like aiming a thermonuclear warhead at a mosquito. The overwhelming majority of long-term survivors I've known have chosen not to take AZT."  The last surviving patient from the original AZT trial, according to Burroughs Wellcome, died recently. When he died, he had been on AZT for three and one-half years. He was the longest surviving AZT recipient. The longest surviving AIDS patient overall, not on AZT, has lived for eight and one-half years.  An informal study of long-term survivors of AIDS followed 24 long-term survivors, all of whom had survived AIDS more than six years. Only one of them had recently begun taking AZT.  In the early days, AZT was said to extend lives. In actual fact, there is simply no solid evidence that AZT prolongs life.  "I think AZT does prolong life in most people," says Dr. Bruce Montgomery of the State University of New York City at Stony Brook, who is completing a study on AZT. "There are not very many long-tern survivors, and we really don't know why they survive. It could be luck. But most people are not so lucky."  "AZT does seem to help many patients," says Dr. Bernard Bahari, a New York City AIDS physician and researcher, "but it's very hard to determine whether it actually prolongs life."  "Many of the patients I see choose not to take AZT," says Dr. Don Abrams of San Francisco General Hospital. "I've been impressed that survival and lifespan are increasing for all people with AIDS. I think it has a lot to do with aerosolized Pentamidine [a drug that treats pneumocystis carinii pneumonia]. There's also the so-called plague effect, the fact that people get stronger and stronger when a disease hits a population. The patients I see today are not as fragile as the early patients were."  "Whether you live or die with AIDS is a function of how well your doctor treats you, not of AZT," says Dr. Joseph Sonnabend, one of New York's City's first and most reputable AIDS doctor, whose patients include many long-term survivors, although he has never prescribed AZT. Sonnabend was one of the first to make the simple observation that AIDS patients should be treated for their diseases, not just for their HIV infection.  Several studies have concluded that AZT has no effect on the two most common opportunistic AIDS infections, Pneumocystic Carinii Pneumonia (PCP) and Kaposi's Sarcoma (KS). The overwhelming majority of AIDS patients die of PCP, for which there has been an effective treatment for decades. This year, the FDA finally approved aerosolized Pentamidine for AIDS. A recent Memorial Sloan Kettering study concluded the following: By 15 months, 80% of people on AZT not receiving Pentamidine had a recurring episode. "All those deaths in the AZT study were treatable," Sonnabend says. "They weren't deaths from AIDS, they were deaths from treatable conditions. They didn't even do autopsies for that study. What kind of faith can one have in these people?"  "If there's any resistance to AZT in the general public at all, it's within the gay community of New York," says the doctor close to the FDA approval, who asked to remain anonymous. "The rest of the country has been brainwashed into thinking this drug really does that much. The data has all been manipulated by people who have a lot vested in AZT."  "If AIDS were not the popular disease that it is - the money-making and career-making machine - these people could not get away with that kind of shoddy science," says Bialy. "In all of my years in science I have never seen anything this atrocious." When asked if he thought it was at all possible that people have been killed as a result of AZT poisoning rather then AIDS he answered: "It's more than possible."  August 17, 1989: The government has announced that 1.4 million healthy, HIV antibody-positive Americans could "benefit" from taking AZT, even though they show no symptoms of disease. New studies have "proven" that AZT is effective in stopping the progression of AIDS in asymptomatic and early ARC cases. Dr. Fauci, the head of NIH, proudly announced that a trial that has been going on for "two years" had "clearly shown" that early intervention will keep AIDS at bay. Anyone who has antibodies to HIV and less than 500 T-4 cells should start taking AZT at once, he said. That is approximately 650,000 people. 1.4 million Americans are assumed HIV antibody-positive, and eventually all of them may need to take AZT so they don't get sick, Fauci contended.  The leading newspapers didn't seem to think it unusual that there was no existing copy of the study, but rather a breezy two-pages press release from the NIH. When SPIN called the NIH asking for a copy of the study, we were told that it was "still being written." We asked a few questions about the numbers. According to the press release, 3,200 early AARC and asymptomatic patients were devided into two groups, one AZT and one placebo, and followed for two years. The two groups were distinguished by T-4 cell counts; one group had less than 500, the other more than 500. These two were then divided into three groups each: high-dose AZT, low-dose AZT, and placebo. In the group with more than 500 T-4 cells, AZT had no effect. In the other group, it was concluded that low-dose AZT was the most effective, followed by high-dose. All in all, 36 out of 900 developed AIDS in the two AZT groups combined, and 38 out of 450 in the placebo group. "HIV-positive patients are twice as likely to get AIDS if they don't take AZT," the press declared.  However, the figures are vastly misleading. When we asked how many patients were actually enrolled for a full two years, the NIH said they did not know, but that the average time of participation was one year, not two.  "It's terribly dishonest the way they portrayed those numbers," says Dr. Sonnabend. "If there were 60 people in the trial those numbers would mean something, but if you calculate what the percentage is out of 3,200, the difference becomes minute between the two groups. It's nothing. It's hit or miss, and they make it look like it's terribly significant."  The study boasted that AZT is much more effective and less toxic at one-third the dosage than has been used for three years. That's the good news. The bad news is that thousands have already been walloped with 1,500 milligrams of AZT and possibly even died of toxic poisoning - and now we're hearing that one third of the dose would have done?  With all that remains so uncertain about the effects of AZT, it seems criminal to advocate expanding its usage to healthy people, particularly since only a minuscule percentage of the HIV-infected population have actually developed ARC or AIDS.  Burroughs Wellcome has already launched testing of AZT in asymptomatic hospital workers, pregnant women, and in children, who are getting liquid AZT. The liquid is left over from an aborted trial, and given to the children because they can mix it with water - children don't like to swallow pills. It has also been proposed that AZT be given to people who do not yet even test positive for HIV antibodies, but are "at risk."  "I'm convinced that if you gave AZT to a perfectly healthy athlete," says Fedorko, "he would be dead in five years."  In December 1988, the Lancet published a study that Burroughs Wellcome and the NIH do not include in their press kits. It was more expansive than the original AZT study and followed patients longer. It was not conducted in the United States, but in France, at the Claude Bernard Hospital in Paris, and concluded the same thing about AZT that Burroughs Wellcome's study did, except Burroughs Wellcome called their results "overwhelmingly positive," and the French doctors called theirs "disappointing." The French study found, once again, that AZT was too toxic for most to tolerate, had no lasting effect on HIV blood levels, and left the patients with fewer T-4 cells than they started with. Although they noticed a clinical improvement at first, they concluded that "by six months, these values had returned to their pretreatment levels and several opportunistic infections, malignancies and deaths occurred."  "Thus the benefits of AZT are limited to a few months for ARC and AIDS patients," the Fench team concluded. After a few months, the study found, AZT was completely ineffective.  The news that AZT will soon be prescribed to asymptomatic people has left many leading AIDS doctors dumbfounded and furious. Every doctor and scientist I asked felt that it was highly unprofessional and reckless to announce a study with no data to look at, making recommendations with such drastic public health implications. "This simply does not happen," says Bialy. "The government is reporting scientific facts before they've been reviewed? It's unheard of."  "It's beyond belief," says Dr. Sonnabend in a voice tinged with desperation. "I don't know what to do. I have to go in and face an office full of patients asking for AZT. I'm terrified. I don't know what to do as a responsible physician. The first study was ridiculous. Margaret Fishl, who has done both of these studies, obviously doesn't know the first thing about clinical trials. I don't trust her. Or the others. They're simply not good enough. We're being held hostage by second-rate scientists. We let them get away with the first disaster; now they're doing it again."  "It's a momentous decision to say to people, 'if you're HIV-positive and your T4-cells are below 500 start taking AZT,'" says the doctor who wished to remain anonymous. "I know dozens of people that I've seen personally every few months for several years now who have been in that state for more than five years, and have not progressed to any disease."  "I'm ashamed of my colleagues," Sonnabend laments. "I'm embarrassed. This is such shoddy science it's hard to believe nobody is protesting. Damned cowards. The name of the game is protect your grants, don't open your mouth. It's all about money... it's grounds for just following the party line and not being critical, when there are obviously financial and political forces that are driving this."  When Duesberg heard the latest announcement, he was particularly stunned over the reaction of Gay Men's Health Crisis President Richard Dunne, who said that GMHC now urged "everybody to get tested," and of course those who test positive to go on AZT. "These people are running into the gas chambers," says Duesberg. "Himmler would have been so happy if only the Jews were this cooperative." 

In this very special episode of VAX ON, Matthew and Elura proudly welcome vaccine myth-buster Ms. Information and Krishna Stone (from Gay Men's Health Crisis) live in studio. These four powerhouse personalities get raw and honest about the crisis of our time; vaccine misinformation, COVID-19's impact on the LGBTQ community, and how the world's problems can be solved with Drag Queens.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

I hosted a special show highlighting World AIDS Day in The Locher Room on Tuesday, December 1, 2020. World AIDS Day provides an opportunity for people worldwide to unite in the fight against HIV, to show support for people living with HIV, and to commemorate those who have died from an AIDS-related illness. Joining me for a frank conversation about the state of HIV / AIDS in America are two GMHC staff members, Krishna Stone, the Director of Community Relations in the Communications Department at Gay Men's Health Crisis and Gregg Bruckno, who is a long-term survivor and works with long-term survivors. GMHC is the world's first HIV/AIDS service organization and their mission is to end the AIDS epidemic and uplift the lives of all affected.I am also thrilled to have a very good friend Tyler J. Helms joining in the conversation. Tyler at 28 years old shared his HIV status bravely with the world on December 1, 2009 in a Facebook post. He has never shied away from sharing his thoughts, feelings and complete honesty about his life experiences and living with HIV in New York City. If you haven't read one of Tyler's blog posts I highly recommend you do. https://www.tylerjhelms.com/.

JAVIER MUÑOZ is an actor and activist whose impressive body of work spans theater, film and television. Javier is best known for co-creating the role of, and starring as, "Alexander Hamilton” in the cultural-phenomenon musical Hamilton on Broadway for two years, after Lin-Manuel Miranda departed the show (and was his alternate prior to that).  He got his break starring as “Usnavi” in In the Heights on Broadway, also created by Miranda. Javier will soon star in the dark comedy indie feature, Monuments. On the TV side, he's appeared on Shadowhunters, Blindspot, Quantico, Full Frontal with Samantha Bee and will soon be heard voicing the character of “Ohm” on Disney's upcoming animated series Eureka. Recent theater credits include The New Englanders at MTC and the starring role in the North American premiere of Stephen Lloyd Helper's A Sign of the Times.  Javier is also an outspoken activist for LGBTQ+ rights and a Global Ambassador for (RED), which fights to end HIV/AIDS. Muñoz was honored with the prestigious OUT100 "Breakout of the Year" award in 2016, as well as the Howard Ashman Award by the Gay Men's Health Crisis (GMHC). Javier now serves on the Board of GMHC as well.Weekly Round-Up:Read The Great Believers by Rebecca MakkaiWatch the short documentary, Short Fuse about Danny Sotomayor, a Chicago activistListen to Slate's What's Next podcast episode “Larry Kramer Wouldn't Be Quiet” Read about Javier Muñoz DaySupport and learn more about the organizations Javi mentions: GMHC, Broadway Green Alliance, and BCEFA.

There are so many areas of public relations and you may not realize it, but you want a specialist in your field for the most part. Not all PR is created equal so finding an expert in your area is a good way to make sure you're getting what you need. In this discussion we'll speak with Anthony Hayes, president and founder of The Hayes Initiative, a boutique, certified LGBTQ-owned and operated public affairs and strategic communications firm in NYC. His 18 years of experience in the field have found Anthony serving on Hillary For America's nation advance team specializing in crisis management and spending two years as vice president of  Public Affairs and Policy at GMHC, the nation's leading and first HIV and AIDS service organization.Support the show (https://www.thesilvertelegram.com/the-pr-playbook-podcast-1)

Ruth Ben-Ghiat is a historian and commentator on fascism, authoritarian leaders, and propaganda — and the threats these present to democracies. As author or editor of seven books with over 100 op-eds and essays in media outlets including CNN, The New Yorker,  and The Washington Post, she brings historical perspective to her analyses of current events. Her insight into the authoritarian playbook has made her an expert source for television, radio, podcasts, and online events around the globe.  Ben-Ghiat is Professor of History and Italian Studies at New York University and an Advisor to Protect Democracy. She is also a historical consultant for film and television productions. She is a big fan of electronic music, which is her preferred soundtrack while writing. She practices yoga several times a week. Ben-Ghiat’s work has been supported by Fulbright, Guggenheim, and other fellowships. Her books Fascist Modernities and Italian Fascism’s Empire Cinema detail what happens to societies when authoritarian governments take hold, and explore the appeal of strongmen to collaborators and followers. Growing up in Pacific Palisades, California, where many intellectuals who fled Nazism resettled, sparked her interest in the subject.  With Strongmen: From Mussolini to the Present (Norton, November 10th, 2020), which is now available she offers a blueprint for understanding and resisting authoritarianism.   Judy Gold's new book YES I CAN SAY THAT! :When They Come for the Comedians We Are All in Trouble Judy has written and starred in 2 critically acclaimed, Off-Broadway hit shows: The Judy Show – My Life As A Sitcom, (Outer Critics Circle Nom) and 25 Questions for a Jewish Mother, (GLAAD Media Award – Outstanding NY Theater, Drama Desk Nom – Actor). The book with the same title based on more interviews with Jewish Mothers was nominated for the prestigious Quill Award. Judy received rave reviews as Gremio in the all female The Taming Of The Shrew for NYC’s 2016 season of The Public Theater’s Shakespeare in the Park. She has co-starred in the Off-Broadway productions of Clinton! The Musical, Disaster! The Musical, Love Loss & What I Wore, and The Vagina Monologues. Judy’s most recent TV appearances include guest-starring roles on Louie, Broad City, The Unbreakable Kimmy Schmidt, The Jim Gaffigan Show, Inside Amy Schumer, Difficult People, 30 Rock, 2 Broke Girls, Melissa & Joey, The Big C, and she is recurring on the upcoming new series on TBS Search Party. She and her family appeared on ABC’s Celebrity Wife Swap, and Judy has competed on TFN’s Rachael vs. Guy and Chopped All Stars. She appears regularly on The Steve Harvey Show and has made numerous appearances on The View, The Today Show, The Wendy Williams Show and The Nightly Show with Larry Wilmore. She is an original cast member of Tru TV’s Worlds Dumbest. Judy is a frequent contributor for CNN, & MSNBC.  Judy has also toured with The Moth. Judy can be seen doing stand-up regularly at NYC’s top comedy clubs including The Comedy Cellar, Carolines on Broadway and Eastville Comedy Clubs, and recently had a sold-out run at Feinstein’s 54 Below. Judy has had stand-up specials on HBO (Cable Ace Award), Comedy Central and LOGO and was twice nominated for The American Comedy Award for Funniest Female Comedian. Judy has appeared in numerous documentaries including, The Aristocrats, The Last Laugh, When Jews Were Funny. Judy’s popular weekly podcast Kill Me Now, is on CBS Network. Judy has guest written articles for The New York Times, The Wall Street Journal, The Huffington Post, CNN.com, and more. She is an ambassador for The Hetrick Martin Institute, and on the board of GMHC. Judy won 2 Emmy awards for writing and producing, The Rosie O’Donnell Show. Also Check out Judy's podcast Please consider a paid subscription to this daily podcast. Everyday I will interview expert guests,usually 2 or more on a wide range of issues. I will continue to be transparent about my life, issues and vulnerabilities in hopes we can relate, connect and grow together. If you want to add something to the show email me StandUpwithPete@gmail.com Join the Stand Up Community Stand Up is also brought to you this month by GiveWell.org GiveWell is a nonprofit dedicated to finding outstanding giving opportunities and publishing the full details of our analysis to help donors decide where to give. GiveWell.org/Standup Pete on Twitter Pete On Instagram Pete Personal FB page Stand Up with Pete FB page

Oppressive dictator regime. Sexual abuse. Drugs. Sex work. Incarceration. Transitioning. Actress. Trans rights and sex worker rights advocate. Positivity embodied. Fighter. Cecilia Gentili grew up in an oppressive dictatorship in Argentina and fled to the United States in her 20s for a better quality of life. She’s battled drug addiction, imprisonment, and ICE; now Gentili is fighting another battle: trans and sex worker rights nationwide. Gentili founded Transgender Equity Consulting in 2019 after having served as the director of policy at GMHC, the world’s first and leading provider of HIV/AIDS prevention, care, and advocacy. Listen as she discusses the reality of sex work and sex trafficking, transitioning in a time when there was barely a word for it, and finding beauty amidst fear and persecution on this episode of SheVentures.

Captain Michele Fitzsimmons is an 18-year veteran of the New York City Fire Department. She currently is the Department’s highest-ranking, senior woman in fire operations as the Company Commander of Ladder 12 in the Chelsea neighborhood of Manhattan. From 2002 through 2004, she was the president of FireFLAG, the FDNY’s Gay and Lesbian organization. In 2007, she co-founded Phoenix Firecamp, a weeklong sleep away camp that introduces teenage girls to the fire service. She continued as a camp instructor for seven years at the annual program. Then, from 2013-2015, she was an instructor at FDNY's Probationary Firefighter School. She is a graduate of the FDNY Officers Management Institute—a program offered by Columbia Business School Executive Education. She has been a Guest Lecturer at Fire Service Women of Ontario, University of Pennsylvania's Wharton Business School and Graduate School of Education. She has presented on holding a position of leadership in a male dominated field as well as decision making while working with Mission Critical Teams. Prior to joining the FDNY, Michele worked at GMHC from 1993-2001. GMHC is the world’s first and leading provider of HIV/AIDS prevention, care and advocacy. Her last three years there were spent as a coordinator of the Lesbian AIDS Project. 

EP019 - Future of Ownership Deep Dive http://www.vehicle2.getspiffy.com Episode 19 is a deep dive into changing ownership models, recorded on Wednesday, September 4th, 2019. Scot breaks down the past, present, and future states of car ownership, including: The three phases of auto ownership; from birth, through the lease and financing adolescence, and into the digital present. Who will claim the largest share of the $1.2 trillion transportation industry in the US? A look at where car ownership stands today and identifying the largest shifts from traditional dealerships. Breaking down the pros and cons of every rising trend in ownership, such as ride-sharing, car-sharing, and subscription models. Conservative and radical projections for the impending shift in vehicle sales, expected over the next decade. The hopeful future, where you can turn your car into an autonomous taxi. We recommend following along with Scot’s presentation from the Auto Intel Summit, which you can download here. If you enjoyed this episode, please write us a review on iTunes! The four pillars of Vehicle 2.0 are electrification, connectivity, autonomy, and changing ownership models. In the Vehicle 2.0 Podcast, we will look at the future of the auto industry through guest expert interviews, deep dives into specific topics, news coverage, and hot takes with instant analysis on what the latest breaking news means for today and in time to come. This episode was produced and sound engineered by Jackson Balling, and hosted by Scot Wingo.   Transcript: Scot:    Welcome to the Vehicle 2.0 Podcast. I'm your host, Scot Wingo. This is episode 19, being recorded on September 4th, 2019. We hope you've enjoyed the last six episodes, which we recorded live at the Auto Intel Summit. And today we are going to do our first in a series of deep dives. A deep dive episode is where we spend the entire episode. It's going to be a little bit longer, so that may take you a couple listens to get through, but we're going to do a deep dive into one of the vehicle 2.0 concepts as a refresher. The Vehicle 2.0 framework has four components. We talk about the electrification of vehicles, autonomous vehicles, connected car, and then last but not least, ownership. And that's what we're going to spend today on. This is actually a version of a presentation I presented at the Auto Intel Summit. This is going to be a unique podcast because it actually does have a pdf that goes along with it that will enhance the podcast. Scot:    So if you're listening in your car or while you're exercising, the audio will be fine alone. But if you are at a computer, you may want to pull up the PDF. If you go to our show notes, you'll find the link to that pdf there. And I do recommend you pull that up now. So we'll assume that you guys have found that and jump right into this. So one of the, I come from the ecommerce world and one of the things I found interesting about the auto world is in the ecommerce retail world, everyone is squarely on board with the fact that the pace of change is logarithmic now. So for example, Sears was started like 150 years ago and then now is almost bankrupt because that company did not keep up with the pace of change that's happening coming into the auto industry. You're looking at another industry that's kind of over right around a hundred years old. Scot:    And it's really interesting. I don't think I'm, as I've talked to folks from the various constituents of dealers and OEMs and whatnot I don't think that the industry has really caught up to that pace. So one of the things that I like to show is a chart which is for those of you falling along is essentially slide two, page two. And this shows the rate of adoption of different technologies. So what's happening is we as humans, you know, we wake up every day and we kind of work our work our eight hours and, and our awake for 12 to 16 hours and we go to sleep. And every day is very linear. A lot of the change we're dealing with is logarithmic. So logarithmic change happens in a, you know, powers of 10 effectively. So what used to take a hundred years can now take 10 years. Scot:    So I'll give you a real world example of that. So for example microwaves I remember I'm from a small town in South Carolina. I remember our first microwave was like $900 is a huge investment. And we were one of the first people in, you know, not only my neighborhood, but probably our city to have a microwave. Microwave's took a good 50 years to get to the adoption rate where they're at over 90%. Now. You'd go to Walmart, you know, now they're essentially a, and everyone has one. If you look at the adoption rate of this kind of technologies, what's happened in the last 10 years and this is because we've got all these platforms now, like smartphones and digital payments and whatnot, it's taking a lot less time for things to get to 100%. So if you look at social media, Facebook went from zero to over a billion users in about five years. Scot:    Uber went from zero to, you know, near a billion users very, very rapidly. So, so what we're dealing with is a rate of change that we as humans, and especially if you're in an industry that has been slower moving is frenetic. And I think that's a good backdrop as we think about these different ownership models. You know, will, how fast will these things happen and what should, should you do if you're in one of the, the industry and you're going to be impacted by that. So let's dig into ownership. So what we're going to talk about today is a little history about car ownership. I think it's always helpful to make sure we're all on the same page about where we're coming from. And then also in that vein, what's at stake, why, why should we even think about this, these new ownership models. Scot:    Where are we today with these models and then what's the future hold? So I think of the US ownership and kind of a model of three phases. The first phase we'll call that the birth of car ownership. And that's from 1908 with introduction of the model t by Henry Ford to 1945. So kind of post World War II. Then we go from 1945 to 2006. That's the ownership adolescence phase. And then last, what we're in now is what I call the digital phase, which is 2007 to 2019 let's dig into the birth phase. So in the birth phase, we had kind of the first cars coming out in 1908, as I mentioned. And those were essentially, you had to buy them outright. So there was no purchase plan or anything like that. But a an interesting company started called the Ford Delivery Company and they were the first rental car company and they did this per mile, so you would pay, you know, something like 10 cents per mile. Scot:    So cars were very novel. They wanted to get people in them. And they came up with this interesting kind of rental car model. So real cars didn't really become super popular until later, but that was the first introduction of that model of car ownership essentially is a, almost like a, a, a test drive, an extended test drive. Then in 1919 GMHC came out and introduced financing. So you used to have to pay for cars upfront and then they actually introduced financing so you could pay for them over a year. So that's kind of fun to think through, you know, all right. Now you know, let's say one of these cars was the equivalent of I don't know, $30,000. Essentially the financing back in those days was essentially in a, it was almost more like a Stallman plan to pay for it over a year. Scot:    Obviously a financing has changed dramatically over the years, but that was, those were kind of the ownership models in the early phases. So buying outright a financing was introduced. And then rental car, then we go into the adolescence. And so an after 1945 in the fifties, leasing was introduced, leasing was before then before the fifties, leasing was popular for commercial vehicles, but it had not been applied to, to non-commercial or individual ownership type models. A company called U s leasing came out and, and essentially brought that in. Did we had a really long period of time where there wasn't a lot of innovation and car ownership. So we go literally from 50 years, from 1950 to 1999. And the big innovation in 1999 is Zipcar. So Zipcar was founded by two folks that went on a European vacation. And they were really surprised and pleased that in, I believe they were in Germany where they found this car sharing model. Scot:    We're in Germany. They could go and find a, a car in a dock area rent that car and drive it around for the day and then return it. They thought that model would do well in the United States. So they founded the companies of car. So now we have the introduction of car sharing here in the very early days in 1999 now that brings us to where we're gonna spend the bulk of our time, which is the digital phase, which started 2007. I anchor this on 2007 because that's when the iPhone was introduced iPhone one. And if you remember, remember iPhone one, it was very controversial, a Nokia and Microsoft laughed at it and said you know, not only is it a terrible phone for making calls, but it's pretty much useless. No one's going to own these things. Boy, were they wrong? So the, the genius of the iPhone, and this didn't come along until iPhone two was the app store. So that's, that's where the iPhone became this open platform that exposed you know, caused the creation of a lot of these new models that we're going to dig into. So it's really important. And, and that's why I anchor the digital phase on the birth of the iPhone. Scot:    So what, what the iPhone has allowed to be created is a whole new model called ride sharing and ride sharing. Has an interesting history. In 2008 Uber Cab launched, which was essentially going to put an app overlay on top of the existing taxi infrastructure. That didn't work out very well. And then Uber moved to more of a model around black cars sort of limousine type vehicles. And then they had a competitor in San Francisco called lift that launched in 2012. And Lyft was really person to person ride sharing. So, so trying to figure out you have all these folks out there that are willing to drive other people around. They don't know each other. But could we use our phones as a way to not only connect those people but get to a destination safely? In response to lift, I'm kind of going to the person to person ride sharing model. Scot:    Uber launched, which was well into the ride sharing world on the taxi side or the, the limo side Uber came out with Uber X, which is the person to person writing platform. So from there we were off to the races and here we are in 2019 and obviously both those companies are, are quite large and public. Now the other interesting model that has been introduced a couple of years ago is it kind of person to person car sharing. So, so you know, when I think of Uber and Lyft, that's ride sharing. So someone owns a vehicle and they're going to drive you. That's ride sharing. Car Sharing is where you're essentially you know getting a vehicle in, from someone in, it's either a, B to c kind of model like Zipcar. So that business is car sharing with you or a person is car sharing with you. Scot:    These, these businesses were kind of born out of the airbnb ethos of all right. People have a second home or a vacation home or a room in their house or a guest house or something like that. And they want to rent it out to folks you know, person to person. That's how airbnb was born. So a lot of these care show, car sharing, person to person, car sharing, companies use that. A lot of the same language and a lot of the same thinking in their businesses. The, the two big guys here are Toro and get around. So this is where you're seeing a lot of innovation right now. It's kind of the next wave behind the ride sharing companies. Uber and Lyft is in the person to person car sharing segment. So we have Toro Toro has raised 438 million obviously a, I think that puts it into what they would call a unicorn status in silicon valley. Scot:    So over a billion dollar evaluation. And their competitors get around who hasn't raised 443 million. So you know five, 5 million more than Toro. So these companies are raising significant capital, which indicates that they're kind of in their hyper-growth phases and making a run at, at, you know, becoming large companies, possibly ips. In the B to B side of car sharing, you have maven and cargo, which we'll talk about later. Another area that's really popular from a press standpoint but less popular consumers is vehicle subscriptions. So there's a soccer company called clutch, which is now owned by Cox Automotive and they they essentially power a lot of the car sharing subscription programs out there. And then some of the companies have actually done their own. So a lot of the OEMs are expanding, experimented with this. So Volvo has care by Volvo. Scot:    Cadillac had, they actually closed us down book by Cadillac. BMW has accessed by BMW, Mercedes bins has the Mercedes Benz collection and Porsche has Porsche passport. There's also some individual dealers that are experimenting with this model. And a lot of other kind of startups in this area like drive, black tie and prime flip. So in conclusion, if we kinda think about these three phases, what we end up with is seven different ownership models for cars that are out there today. If we go back to the birth, we have number one, which is outright ownership, and then number two, finance in three rent. Then as we go into the adolescence phase, we have leasing. So that's our fourth car sharing and I kinda count car sharing as one. But there's two flavors of car sharing. There's the B2B side and the person to person side. Scot:    And then we have ride sharing and subscriptions. So those are our seven ownership models that we're going to dig into. Before we do that, let's look at what's at stake. Why are people investing 500 million, you know, over $1 billion just in one of these segments? Well, the u s consumers spend over $1 trillion a year on transportation and they drive over one and a half trillion miles just in the u s alone in passenger vehicles. There's 280 million vehicles on the road today. So, you know, this is a really big addressable market. If you could just get, you know, 10% of that, that's $120 billion market. Essentially. And if you can get 5% of that you know, just 5% of the market, it's $60 billion. So while we see these companies all have very, very small market shares, we have such a big number that spent on transportation every year that you can build really big companies here. Scot:    Even if they're going to be having a one, 2% type impact. So that's very attractive to both entrepreneurs and investors. Also, you know, I mentioned earlier, you have an industry that's been around for over a hundred years and the car ownership experience, you know, I remember going with my dad when I was like 10 and buying a car and then now when I buy a car, it's almost exactly the same experience. You know, you, you go, you meet that sales guy, no one really loves that process. Then you have to negotiate with his manager. Then you sit down and you go through a very long kind of you know, process to, to end up buying the vehicle with all these financial options and things thrown at you. So, so you're looking at an industry that, that I think has, you know, hasn't really changed in a hundred years, has pretty low customer satisfaction. Scot:    You know, the, the whole car buying and owning process is not amazing. Compared to kind of compare that to like an Amazon prime type experience. There's a lot of room to go there. Another factor here is the cost to buy a new vehicle has gone up substantially. So if you look back kind of 10 years, a new vehicle on average was $28,000. Well, with all the new you know, the, the user consumer preferences towards SUV type vehicles, all the new electronics and all the new features and functionality, the average vehicle cost has gone up to 35,000. So that, that's pretty material, right? That's a 7,000 you know, almost like a 30% increase over 10 years and the price of a new vehicle and some of that is self inflicted by consumers by, by what they're choosing. But that, that's Kinda the, the essentially owning a car has gotten way more expensive in just 10 years. Scot:    The, the cost of owning and operating a car. So you would think a lot of this new technology, you would reduce that. Actually it's gone up pretty substantially. So the cost of owning and operating a car is about $9,000 a year right now. So, so that, that's pretty substantial. And that's those two things create demand at the consumer level for new models. Okay. So let's dig into each of these models. So we have outright ownership, financing, leasing, renting, ride share, car share with the two flavors of B2B and p to p, a person to person. And then subscriptions. So for those of you following along, I'm going on to page 21 in the, the presentation. So if we look at ownership finance, lease together as kind of a subsection of those ownership models. Last year in the United States, 17.2 million cars were sold. Scot:    11.8 million of those were truck SUV. So you can see that a, you know, substantially large percent of these are now are in that truck SUV category. Many, many manufacturers have stopped making sedans. So, so the consumer demand for sedans is way down. The, the average alone on these vehicles. If we, if we look at how many people buy outright, only 14% of consumers buy a vehicle outright, which makes sense. This is, this is a pretty expensive, you know, this is kind of pretty much you know, a year's worth of income that you would have to accumulate to buy a car outright. So because of that, 86% of people finance their vehicles within that finance bucket, 30% are leased and 70% are traditional car loans. That always surprises people. I think a lot of people I talked to lease vehicles and they are surprised. Scot:    Other people aren't leasing, but again, 70% are doing the finance kind of model where they're gonna own it out right after four or five years. And then more you know, I would say a more fluent segment is leasing the vehicle at 30%. And then that leasing segment it's interesting as we think about ownership, a lot of people kind of think, all right, I'm going to pay, you know, two, three, four or $500 a month for, for a car. And that's kind of going to be a steady state. And this is Kinda like a gateway into the subscriptions that we'll talk about the average loan for those folks that are financing the vehicle, the average loan is over 30,000, $800. And today you're looking at a 68 month term. So what is that? Five and half years. So, so five to six years. Scot:    So, so folks are really you know, the financing vehicles have grown up to have a pretty low monthly payment, but what they're doing is they're just pushing out the terms. Compared to that first kind of installment plan I talked about, which was paid a year, the rental car market is fascinating. And, and here at Spiffy, we, we work a lot with rental car companies. When you talk about this for folks outside the industry, you know, what your intuition would say is, wow, ride sharing. The, the rise of ride sharing miles from Uber and Lyft must really be hammering these rental car companies. And what you actually find out is there's a little bit of truth in there, but then there's also a side to that and unintended consequence you may not be aware of. So let's look at that. So there's over 2 million vehicles in the United States active today. Scot:    It's a $28 billion a year industry. And that industry grows right in line with GDP. So it's growing three to 5%. Just like GDP, the, the impact. What's interesting about rental cars is yes so they think about trip duration. So, you know, they have a segment of users that will do kind of day trips. So that same, same day rental, same day return. Then you have one, one, two, three, four, five day, and then greater than five day increments. What's interesting is, so some of the public companies, so, so hertz for example, listening to their conference calls, what they're seeing is ride sharing is hurting the super small trips. So as most impacting day trips and then one day, but then two day plus have not been impacted by ride sharing. So, so they're seeing, I think they've taken about a, a 7% hit on these shorter trips due to ride sharing. Scot:    So then you would think, you know, all right, maybe that's 10% of what they're doing. So, so you, you would expect them to be shrinking, not growing three to 5%, but where they're making up for that actually is on the tail end. So prior to ride sharing these companies would hold vehicles up until about 50,000 miles, then they would wholesale them out at auction. What they're doing now they have so much demand for longterm rentals from Uber and Lyft drivers that they're now keeping the vehicles from 50,000 miles to 80,000 miles. And in that, those 30,000 miles they're renting them out on 30 day periods into the Uber and Lyft networks. And that's actually more profitable for them because the short trips are very expensive and not super profitable for, for the car rental companies because they, they, you know, if it costs $30 to turn around a car and it comes in and out every day, then you haven't made enough revenue to cover the turnaround. Scot:    So what's happening is they're actually, they've lost, let's call it 7% on the short trips, but they're making up that plus a lot because it's more profitable on the back end of the life of the vehicle by putting them into the car networks. So you may not realize it, but the, you know, especially in big Metros, the, the car, your Uber or Lyft driver is driving, could very well be a rental that they've done a 30 day rental from Hertz, Avis enterprise or of their imprints. So, so that's really interesting and that's a, is fascinating to see the unintended you know, the, the counterintuitive reaction that's happening in these things. It also shows, I like to talk about these ownerships models as if they're separate things, but they actually are really starting to overlap and interesting and fascinating ways that we'll look at. Now let's look at ride sharing. Scot:    So that's the rental cars and now we're into ride sharing. So again, in my, my, my vocabulary ride sharing is you know, you have a driver that comes and gets you. You're usually using an app to hail that driver. And Uber and Lyft are the big players in the United States. So there's a lot of buzz around this obviously, and you've got two large public companies that have been created, multibillion dollar companies. But really when you, when you look at it if you look at 2018 and this is, this is government data that essentially from the Department of Transportation and if we look at 2018 really one and a half a million miles have been from ride share which is 0.9%. So we're not even like 1% of of transportation miles yet from rideshare. So, so very, very small overall and it's forecasted to stay about the same. Scot:    But you know increased by 2028 be about 3% of overall miles. So it'll be growing really rapidly, but still it won't even be kind of 5% of miles for the next 20 or 10 years based on the modeling that's out there. So it's still very early days for this and this because the transportation industry is so large, you know, we're, we're, if we're traveling one and a half trillion miles, it takes a lot of, of ride share miles to make it den on them. What I find fascinating is, you know, why are people using ride sharing. You hear in the press beats the drum on this that, you know, people are giving up their cars for ride sharing, but when you actually look at the use cases, I think it's fascinating and it's certainly that's going on in some of the larger Metros like New York, Boston, Chicago, San Francisco. Scot:    But I think once you step outside of those areas, it's really interesting to see why are people using ride shares. So this is from a Wall Street firm called JMP securities. They did a pretty large survey of thousands of ride shares to kind of say, why are you using a ride share? The number one use case at 46% is a trip to the airport. So, you know, this is fascinating. You know, I, I think, I think the, the people that are actually the companies that are impacted the most by ride sharing is airport parking. So folks are doing the math. You know, fortunately here in the Raleigh Durham area parking is like maybe 20 or $30. But in large cities, you know, you can easily pay $100 a day to park your car. If you're at Boston. So you know, the math doesn't make, it doesn't make sense to park your car there. Scot:    So everyone's taking a, a ride share to the airport is the number one use case. The next couple of use cases are a, we're familiar with here at Spiffy because it creates a lot of problems for Uber and Lyft drivers and that is leaving a clar a club or a bar at night. So 33% of consumers that use rideshare are using it when they're out drinking and partying. 16% is at a party. So you add those together and you get what? 49%. and then there's going to a dinner, going to a concert and going to a sporting event. When you roll all those up, it's like 70%. So actually the biggest use case I think of ride sharing is I want to go out, have a good time, and not worry about having a designated driver or getting a DUI when I come out. Scot:    I haven't seen any stats on this, but I, I think there's this probably this interesting freakonomics like study we could look at where I think the rise of ride sharing is probably plummeted DUIs. So, so I think that's, that's great too because we have less people out on the road driving intoxicated. So, so there's this, you know, there's really interesting use case. I don't, when I talk to people in the industry, they don't think about the reason we see this a lot is spiffy is unfortunately when you do transport, a lot of people that mount drinking accidents happen and we call those biohazards. And we, we do a lot of help with those situations here at spiffy way down at 10%. Sub 10% is the use case of my daily commute. So most people are not using Uber and Lyft for their, their daily commute. Scot:    So as we peel the onion on ride share and look at Uber, Uber has all the stats we gave you or as of the reported first quarter of 2019. So these now these companies are public. We have a lot of really good data here. Uber has 6 million active drivers and a 62 million active riders. That's a global number. They don't break that out by the u s but half their businesses. U S so I would say probably 3 million active drivers in the U S and about 30 million active riders in the United States. So, so a lot of, lot of people really using these services. If you think about the u s we have 300 million folks with us. So anything, you know, 30 million active riders would be about 10%. Scot:    I'm looking at Lyft. Lyft has 2 million active drivers, so about the same size as Uber when you compare apples to apples for the u s market. But because Uber invested very heavily in going international. They're about twice the size of Lyft or, or more. They also have Uber eats. Lyft doesn't have that. So Lyft, Lyft has 2 million active drivers, 20 million active riders and delivered over 205 million rides in the first quarter of 2019. When you look at these companies, if you're really interested in this, I strongly recommended recommend when you go public yet to file a document with sec called an s one. So if you googled, for example, Uber s one or Lyft s one, you'll get a really nice you know, this is going to be like a 300 page document that these businesses put together detailing every aspect of their business. I recommend pulling those down, looking through them. Scot:    And then I always the, the way the SEC requires you to draft this it's kind of like all the good stuff's in the middle. So you have to kind of like talk as if your business is terrible. And then you'd talk about some of the good stuff and you have to end with why it could be terrible. A lot of people misread that. And you know, as wow, y w this business is terrible. So the section you want to go to is the management discussion. So the, it's called the management discussion and analysis or the MDA section. It's usually literally about a third of the way through the document. That's, that's really where you get in the heads of the CEO and the team running the company and understand how they think about the business. And that's where you can really get, get really deep understanding of these businesses. Scot:    So, so if we look at in the U S if we look at if we compare where they are Uber versus Lyft effectively in 2016, Lyft had 22% share an Uber pretty dominant at 78%. But Lyft has made a really big push and is gaining share. So as we, as, as we left 2018, which was kinda the last time data was available Lyft had 40% market share, an Uber 60%. So, you know, what lets doing is competing on price and really trying to differentiate. And have happier drivers. They share a little bit more revenue with drivers. Lyft was the first out that let you tip the driver. So really kind of trying to have a different brand kind of model than Uber. Uber had some challenges with their previous CEO and some of the things he said did. And then now they're kind of on the mend with a new CEO, a new, a new kind of trend in the industry. Scot:    And I, I'll kind of put this kind of still inside the ride sharing bucket is we have these new suppliers that are being born that, that will try to supply into the transportation network companies. So a lot of the industry publications will call Uber and Lyft transportation network companies. So there's all these new companies that are supplying in there. Previously I mentioned the rental car companies. So the rental car companies, I would hazard to guess, and there's not a lot of data on this, but just because of their scale are probably the largest suppliers into the TNCs. So what that means is again, Hertz, Hertz, Avis and enterprise essentially taking tail end cars, cars that have a fair amount of miles on them, usually 50,000 up and supplying them into Uber and Lyft drivers. There's also several other companies doing this, such as Hyrecar. And for those falling along, I'm on slide 28. Scot:    You know, so higher car a is really a, a smaller company. I'm thinking about a hundred million in revenue, then went public and they really just provide short term 30 day ish rentals for Uber and Lyft drivers. Lyft is actually, Uber didn't experiment where they would actually lease cars into their own. Drivers. They, they exited that business before they went public and that merged into f a I r so fair is a very large supplier for the TNCs. Lyft is doing it's own program called Lyft express drive. And then another company that's really interesting is in New York called Buggy where, you know, they're, they're essentially doing these short term rentals where you can go in and sign up online and within hours you can have a vehicle. And they've, they've done the math on, I think they have like two or three models that work really well in New York City. Scot:    So I think one is like a Prius and one is a newer Toyota Corolla and they, they're so tied into the networks. They will say, all right, if you want, one of the ways paths you can go through is they'll say, do you want an Uber select vehicle, an Uber XL vehicle or an Uber x vehicle or a vehicle that would be available for Uberpool. And they know those requirements and they have vehicles that meet those requirements. So as a driver you can say, you know, wow, my, my daily driver, I can only do Uber X. And I've heard Uber select is where all the money is in New York. So you can go rent a car that gets you into that Uber select tier from one of these suppliers. So a lot of really interesting kind of innovation happening as a feeder into Uber and Lyft that, that you wouldn't know about, but it's right there under the surface. Scot:    Now let's talk about car sharing networks. So I talked a little bit about Zipcar before. Let's do a little bit of a deeper dive to kind of understand how this was born. So Zipcar, as I mentioned, was started in two, in 1999 and you know, you can imagine before you had a smartphone, it wasn't super useful. So you know what, these are gated. So what the user experience was largely around college campuses and, and areas like that. So you would know, hey, in my college, I'm a student in, at my college campus, I've seen these d zip cars parked and two or three locations, you sign up, you pay a monthly subscription, they could use certain number of miles. If you go over those miles, you pay a per mile fee. But if your student, you know, you could go and say, all right, I really need to run errands. Scot:    So you would go to the grocery store, go to the mall, and then you use the car for four hours and put it back in one of the gated areas. And then you would go, you'd use your desktop essentially to log your, your miles in and out and whatnot. 2009 once the app store is open this, this really took off a lot more because the phone is a much better use case where you can say, now, all right, I am in location X. I press a button and I can, I'm pleased to see there's a zip car three blocks away from me that I can go use. And I can see that there's one there. So you get, so the phone added Geo location, kind of hyper geo knowledge of what's going on. And then availability of inventory, which is really critical to this model because what really stink is if you're a college kid, you walk all the way across campus and then the two zip cars are gone. Scot:    So really bad user case there not having visibility. So the phone has really solved that. So that really took off. They did have some controversy around the founders that got kicked out. New new team was bought in and the company went public in 2011 after kind of two years of hypergrowth after the introduction of the smartphone app they ended up getting acquired by Avis in 2013 for about $500 million. So, so definitely a big success story in, in, in the transportation space. Unfortunately, once they're acquired, Avis hasn't really provided a lot of information. What I can tell you is they're available in 500 cities globally, over 12,000 vehicles out there. The average trip is 47 miles. And then within car sharing, one of the innovations is Zipcar is kind of the earlier model where they're, what were called docked. Scot:    So again, there's these branded parking spaces you have to go to this parking spaces. It can be relatively inconvenient both on the pickup and the return part of this transaction. Especially if, you know, let's say you did all your grocery shopping in the doc for the Zipcar is a fair distance away from your dorm and you're a college student. Now you got to lug all that stuff. You bought a across campus back to your dorm. So a lot of the you know, a lot of the innovation in car sharing has been in the undocked category, but over in the docked category, we do have Maven which I believe is supported by GM. And then that's, that's out there as, as an option as well. The undocked companies. So you have cargo share now reach now, drive now enterprise car share. Scot:    And a lot of the OEMs are testing this. So Toyota has a test in Hawaii called Hui. I don't know how to pronounce that. We'll, we'll call it hooey. So, so a lot of really interesting things going on there that we'll explore. So one of the challenges is the reach. So because there's a business that's owning these, it's got to someone's to pay for the car. Right? so if you look at Maven for example, it's available in like seven us cities. And you know, so Ann Arbor, so a lot of these start in Michigan and, and the Detroit and our Arbor areas are always possible. Chicago, a lot of them kind of start in the Midwest and then go out to the edges. And then another challenge with these car sharing networks is security. There's a high profile Cartago I believe, or may have was maven. Scot:    They had you, it was the Mercedes one, which is car to go. They had 75 vehicles stolen. So, so people you know went to the dark web, they got some, you know, American Express credentials. So they stole credit cards, use those stolen credit cards to get access to the vehicles and then stole the vehicles. And well all of these vehicles have tracking whatnot before the local authorities could track them down. The vehicles were stripped down to the skeleton and all the parts were gone. So a lot of these companies have actually exited the Chicago market because they, they there's a very efficient car theft capability there that, that I don't think you can, you can get around. Well the big news and the car sharing networks is consolidation. So BMW and Daimler both had separate programs and they got into kind of realize, you know, hey let's go in this together. Scot:    If we each kind of, you know, are going to spend tons of money looking at this type of a program that's inefficient. We're all developing the same models. Let's, let's pool our interest. So they reached a joint venture recently here in 2019 that brings Cartago and reach now under one roof. The brands here are a little confusing. So I think they all have this now things, so they have share now, reach now and Parkville all within this, this whole conglomerate. And the share now is the car sharing program that we're talking about. Park now is their acquisition of park mobile. So you know, you, you have some, the jury I think is still out on car sharing, both in the doctrine undocked if it's going to take off, it's going to be the undock. It's also you know, what's interesting is in the ecommerce world, we see brands going direct very aggressively. Scot:    And I think we're gonna see that in the, in the auto world which will obviously disrupt the dealer networks. So most of the experiments in car sharing or from the OEMs here, it's 50, we're under NDA with many in it, you know, OEMs that are doing experiments around car sharing largely in the San Francisco and La areas. So there's a lot going on, even more than than I can report here. And it's mostly the OEMs kind of directly figuring out, you know, is this going to be a whole new model that they should be involved in? And because they're making the cars it kind of is viewed as a verticalization of supply chain in an interesting way. So the jury is still out on that one, not really up to scale. And I would argue subscriptions are kind of in that program where we are seeing a lot of scaling up is the car sharing. Scot:    From a P2P perspective. So I mentioned earlier we're got this kind of very similar Uber versus Lyft battle forming between Toro and getaround. So Toro decided to go wide very quickly. In the, in the early days trows decision was to get an in many cities as quickly as possible. Get around said no, the user experience is more important. We want to have a limited rollout and we're going to ask every one of our car owners, what they do is they use this airbnb language. So a car owner as a host and then a car renter is a guest. They don't use rental language at all because they, they're trying to stay out of all the regulations around rental cars for the consumer. It feels like a short term rental. This a lot cheaper than, than a normal rule. But the companies themselves use airbnb type language. Scot:    So I will, I will adopt that as I talk about them. So get around, requires their, their host, which are essentially the people that own cars. So we'll call this host to have a device installed that gives the guests the iPhone, the smartphone ability to lock in and lock the car and have access to the car. That's really a nice user experience because now you don't have to mess with getting the keys. So, so get around. That device is called Getaround connect. And for the longest, a very long time, it was a required part of it. They've since loosened that up. So if you look at them today, Toro has a 5,000 cities, over 5,000 cities, thousands of cars. They're running this really interesting Porsche host program where Porsche goes in and they say certain hosts that have one or two Porsches available are almost like ambassadors for the brand. Scot:    So you can get a, essentially an extended test drive. So you can go rent at nine 11 for a day from a Porsche host. And that host is going to be able to tell you all about the features and functionality that car and really you know, highlight what's great about a Porsche. So that's an interesting kind of another intersection of the OEMs promoting this, this kind of short term rental model. I'm in the car sharing world. Toro came out with its own device you can install called Toro go. And on the consumer side you can say, all right, I want a Toro in San Francisco that I want a Tesla and I want it to have this device installed. Most recently Toro raised $250 million from interactive court. So you see a lot of the biggest investors in this space are Interactive Corp, Cox automotive car are automotive Kar. Scot:    And then you also have Softbank, Softbank in the world of startups. Softbank is the, the, you know the Mac daddy of the gangster, of investing in, in large companies scaling up and that's who's invested in getting room get arounds in 300 cities. They just acquired a competitor called Drivvy; d, r. I, v, v. Y. Um, and over in Europe which gave them an international presence. They say the average car on their network owns, earns $500 a month. And then they recently raised 300 million from Softbank and they have a partnership with Uber where, you know, again, all these companies are kind of becoming suppliers into the the ride sharing companies, which I know it gets confusing. But you know, you can say let's say you have a second car, you can rent it on, you know, for 30 days to an Uber, Lyft driver through get around. Scot:    So, so a lot of really interesting things going on there. Only compare these two guys according to some of the folks that measure the data here. This is sourced to second measure on, on slide 34, if you're following around, Toro has about 80% market share in the u s and get around 20%. So it looks like it looks like kind of Toro is going to be the Uber and get around. It's going to be the lift, but we'll still see us very early days. Again, these companies have all raised hundreds of millions dollars recently. So, you know, I am, I'm actually starting to see TV ads and things from all these different models out there. The thing that we see as 50 that's interesting is we see this lifecycle with get around in Toro. So, so here's how it works. So let's say you, you you hear about one of these things and you're like, wow, I would love to make some, you know, some extra money from my vehicle. Scot:    So you start, you start putting it on with these networks and you really, the extra capital that you're getting, let's say, you know, a week out of a month you rent a car and you get $150, you know, that's nice and helps you maybe cover your car payment and pay for gas or anything. But then what you start to realize is having someone in your daily driver is Kinda Weird, right? Because it was just kind of strange sharing your car with someone. But then what a lot of people do is they'll buy a second car and that's Kinda like their investment car. And they'll say, or they'll buy a new car and they'll take their primary driver and turn it into their, their car sharing car. So they'll effectively have two cars, a daily one that they live in, and then a second one. Scot:    And they'll, they'll put that out there and they'll reel, they'll start to make $500 a month, they'll pay off that car very quickly and they'll realize that, that that's a really good way to earn, you know, effectively own a vehicle. Pay It off and then start generating cash. So once you pay off that vehicle becomes a cash cow then they'll buy another one, another one, another one. So, so what we find is these power hosts have developed where there's folks that own five to hundreds of vehicles and they're, they're using this you know, they're using these networks to build pretty interesting micro fleet businesses. So, so then they start parking them around airport parking. So this is interesting because now you know, now we're back to airport parking, which is suffering from ride sharing. But if you do want to do a longer term lease from a truck, get around and you're going to lax or SFO what you'll find is most of the parking now is occupied by these types of vehicles. Scot:    So it's Kinda funny how these things all intersect. I do expect this model will have an impact on their rental car company. I don't think the scale is there quite yet. But I think in three or four years you're going to start to hear them have to react to these things. And maybe they'll, they'll actually participate. Or you know, if I'm, if I'm hurt, I start to say, well, why is it fair? These guys can essentially run out cars and not pay all the rental car fees I have to pay and all the regulatory things. And it's gonna be interesting to watch. Just like the taxi industry fought up against Uber and Lyft. I think we're going to see the real car industry start to really kind of come at these car sharing companies. Okay. The last model to look at before we start looking at the future is subscriptions. Scot:    So, so these, these sound good, you know, you're kind of like, all right, I'm already leasing a car. And what if I paid a little bit more and everything's included. So the insurance is included. Everything I think you pay for the gas, but all the maintenance and everything is included in what they offer. That's pretty cool is they all have a different degree of being able to switch cars. So some of the programs, usually you have a different kind of a good, better, best program in these things. So, for example like the let's say the BMW one, you have three tiers icon, the legend and BMW m. So that's where you're going in the m class, which is their highest end. So the icon you have, you know, kind of the three and four series BMWs and the legend, you get the five and six series and then the m you can get kind of like the convertibles and the fancier cars. Scot:    As a consumer, it's an interesting use case because you could say, you know, I have three kids, so during the week I want a, you know, an SUV type car. But on the weekends my wife and I are going to the beach or we're going up to the mountains, we'd like to have a convertible or a different type of vehicle or maybe you need a four wheel drive. So, so there is an interesting use case there. The challenges, the costs. So that BMW when I was telling you about the lowest end is $1,000 a month and then it gets up to about $3,000 a month for the high end. So you know, just feels like it's priced itself way outside of even luxury consumers when you're competing with, you know, that would be nice, but if, you know, I could have one of these BMWs for five or $600 a month, I'm not sure consumers willing to pay 10 x then. Scot:    So, so I'm just not really sure where this is going to go and what we'll have kind of, you know, seems like there's something there, but they've got to figure out how to get the cost way down. It needs to be, you know, the killer app is if we were designing this is it would be lower than my lease payment or, or equivalent and I could do peak vehicle flips and you know and have access to, you know, some vehicles I probably wouldn't normally have access to. So I think we're a long way from there. All right. So those are the seven models and a deep dive into where we are on all of them and what's going on. Where is the future taking us? So we want to conclude here by, by kind of looking forward and I'm on slide 36 for you home gamers. Scot:    So where are we today? Vehicles are only used 5% of the time. So you have, you know, it's largely people's. If you rent as prior, your your biggest asset and if you own a house, it's your second biggest asset. So you're actually using your, one of your biggest assets 5% of the time. And it just feels wasteful. You know, think of all the cars just sitting there parked right now while I'm talking to you. So think of all that real estate that you know, could be green space or bike lanes or parks or whatnot. 89% of trips are single writer. So again, as we think about the environment that's really inefficient. And then again, the average cost of the vehicle is $33,000. So, so where the, the metric I have found that drives a lot of these models about where the future's going is cost per mile. Scot:    Right now we're at a cost per mile and the term kind of ownership model of, you know, again, a finance own outright our lease and about $3 per mile. So, so that's the real key driver. How do we drive that cost down? So electric vehicles are one of the ways, you know, so with electrical vehicles, you're obviously not consuming gas. You know, the cost has come down like on the model threes and some of the other models coming out where you're not having, it's not a luxury kind of a, a vehicle anymore. It's in that you can get vehicles are getting closer to that $33,000 number. The, the key driver though is autonomy. So there's a couple of models here. I'm sorry. So I went out and kind of looked at all the different models about when is Carner ship really gonna Change. Scot:    The first model is from BCG analysis and it's onside 38 for those of you falling along. And what it shows is kind of a, what I call a slow boil. So here we are in 2019 and they really don't show much of an impact until 2030. And a lot of that is from autonomous vehicles, so, so they're kind of saying by 20, 30, 70% of cars will still be you know, individual ownership kind of conventional models. And then 30% will be these, you know, Robo taxis and car sharing is all the models I've talked about outside of individual ownership. So so that, that, that feels right to me because I come from the ecommerce space and you know, we're only about 15% of of sales are e-commerce and we've been at this 20 years and it's obviously a better model, but there's still just a bunch of people that don't trust the security. Scot:    They like going to the store, they love parking, and you know, waiting in line for hours to get stuff. I don't, I don't a hundred percent understand it, but you know but you do see pockets where it's as high as 50, 60, 70%. So, you know, that's one model and I call that kind of the slow Boyle. Then there's the a model that shows crazy fast. And this is from some guys out of Stanford that, that have a model. And they have a company called rethink x that published this and their model, we, the new, they kind of use a miles kind of a metaphor, but it's about the same. And this model, 80%, by 2030, 80% of the cars will not be owned by individuals and 20% will be these new models. And when you, when you dig into how is it possible that, that a smart people are forecasting such different things? Scot:    What you find is it's the autonomy piece. So to get that, to get down from $3 a mile to sub a dollar a mile, which is where as consumer, you will logically then according to these economists, you'll logically choose to not own a car anymore. Because owning a car will be $3 a mile and using one of these other things that will be a dollar a mile, it takes autonomous vehicles to be pretty prevalent in Robo taxis. So that's the real crux of this is when are we going to have, you know, large numbers of miles driven being able to be done by autonomous vehicles. Scot:    A good example of that is on slide 41, where, you know, when we're at $3 a mile, then the addressable market for these new modes of transportation is about $20 billion. So, so large. But once autonomous vehicles get you to a dollar, then it mushrooms up to 750 billion about 150 times the market today. And then once you can get a below a dollar, then it will be 300 times today. So that, that's the real dry or the model. Let's see if you're interested in this. On slide 43 Tesla did a effectively a, a full day on autonomy. And then there you know, there's a lot of really interesting discussion around the technology behind autonomous vehicles, like lidar versus cameras and whatnot. But then at, towards the tail end when Ilan was wrapping up, he talked about Tesla's overall plan to have robo taxis out there. Scot:    So these vehicles will be under $38,000. So call it a Tesla Robo Tock taxi, which is effectively a model, a model three or a model y with kind of a base configuration. And you know with full autonomy, he thinks they can get the cost down to 18 cents a mile. You could charge less than a dollar a mile for a profit of 65 cents. And then this, this vehicle could be out there generating 30 k a year for you in profit. So, so really interesting. The application of electric and autonomy you know, they, I think they can get the miles down to, you know, way below a dollar a mile. But again, you know and of course in typical Elon fashion, he said, we're going to have a million of these in a year. So I, I think that's very aggressive. I think the regulatory environment is not gonna allow that to happen. Scot:    But it is interesting to think through, here's a real car maker thinking through these economics and you know, putting, putting off flagged down at six, 18 cents a mile. The other big trend that's driving the future of transportation is multimodality. So multi-modality is that the kind of the holy grail for transportation is imagine you have an app. This app says OK you tell the app, I want to go from point a to point B, and that may be I'm in New York and I want to go from, you know, Tribeca up to I don't know central park. And that app will tell you here's the optimal, do an optimize on time or, or money or, you know, maybe there's a slider in between there. And depending on what you do, that app is fully dialed into all modes of transportation. Scot:    So that app may say to you, all right, for time, you're gonna take a scooter to the subway stop. And here's, here's, here's 12 scooter companies and you're going to, there's a lime that's close to you and we're going to go ahead and light that up. And you get to the line, you take it to the subway stop, you park it, now you get on the subway and the app has timed it to where you're there two minutes before the trainer eyes. Now that train takes you somewhere and then it puts you on a, you know, now you take a ride, share to the next leg of your journey, et Cetera. So kind of intermingling all these transportation modes from micro mobility on bikes and scooters. Two medium distance from ride, ride sharing and maybe down the road, Robo taxis. And then also intermingle mingling, car sharing. Scot:    So another use case could be, alright, I'm in New York and I want to go to Maine on vacation. So this app says, all right, here's how we're going to connect to this. You know, you're going to take a let's see a bird from here to the subway, that subway is going to take you out to LGA. And you're now going to go to this long distance LGA parking area where there's a Toro waiting for you and we've rented it for the two days you need, and that you're going to take that Toro, do your trip and come back, and now you're gonna have to, you know, the, you know, for whatever reason Toro wants you to return that to a different location. And here's how I'm going to get you home. So that's, that's, that's kind of the big driver of the future of multimodality. Scot:    So everyone's gunning for this. So it's gonna be interesting to see who, who gets there first. You know, you, you obviously, so Uber and Lyft are trying to get there very aggressively. So you have some multi-modality there between, you know, the different ride sharing all the way from, you know, the XL, the black cars to select to scooters. Some of them are starting to pull in there. You had the map companies. So you know, I use, when I go to New York, I use Google maps for this. It does a really good job of telling me, you know, walk here, do this. It doesn't really have the scooter thing in there. And the bike thing I'm not really big on those models, so I'm fine walking to the subway stops and it tells me where to go. The other thing I'll depart with is there's always a lot of interesting unintended consequences. Scot:    So with availability of ride sharing, for example, this is slide 47 you know, what they're finding is over half of the, the ride sharing trips are new miles. So a lot of lot of folks thought, okay, Uber and Lyft are going to really increase utilization. But what's happening is because they've made it so easy for people to go to from point a to point B, people are actually increasing the number of miles they travel. So, so a lot of these are new trips and so you know, one of the surprises is ride sharing is actually increased congestion in big cities like New York, Boston, Chicago, San Francisco. That's, you know, what suffering from that a little bit is public transportation. So if you're in New York, it's actually, you know, a much better user experience to ride a ride hailing vehicle than get a taxi, which would be too expensive. Scot:    So cheaper than a taxi and it's more expensive than public transportation, but it's a better experience. So, so a lot of incremental new miles coming out of unintended consequences. So what's this mean for you? So you're obviously listening to this podcast because you're somehow connected to the transportation industry. You may be an ecommerce person that thinks about package delivery and you know, if we do have these robotaxis that that's going to be a game changer. But, but essentially think who's going to own the vehicles and when are we going to see this? This flip happen largely driven by autonomy. Who's going to maintain all these vehicles once you have more, you know, if we're, if we're kind of currently at a 5% utilization and we take these vehicles up to a hundred, that's a lot more miles per vehicle, a lot more drivers, a lot more maintenance. Scot:    Who's going to do that? What happens to car dealers and these new models where, where do they sit? Are they the guys that are the parking lots and the maintenance for these vehicles? What happens to the OEMs? Do they essentially go direct and cut out dealers or do, does everyone still have a role if you're, if you're not autonomy does, does that mean, you know, that has consumer, you don't really care. The difference between a Volkswagen and Mercedes is no longer a status symbol because you're just using this thing for five miles and you don't really care. What, what's that mean? You know, what happens to the ride share and car share companies when autonomy comes along, they're obviously investing heavily to make sure they, they kind of put themselves out of business in that model. And then, you know, there, there's always a scary side to this kind of stuff. Scot:    But what I found is these kind of really big changes create opportunities that are bigger than the downsides. So, so what does it mean for your business and how can you innovate and be a part of this and capture some of these, you know, hundreds of billions of dollars that are going to spill out when, when this happens. And last, you know, we, we have kind of seven, seven big groups that are really fighting over this. So we have the car sharing networks both docked and undocked we've got the P to p companies, we've got the subscription companies, we've got the traditional rental rental car companies, the ride sharing companies, and then all these companies investing along with, so you've got the OEMs and other companies you know, investing heavily in autonomy. They're all in a collision course trying to fight for this one and a half trillion dollar market. Scot:    And it's gonna be really interesting to watch that. And if you find this topic interesting, you're in the right place. Cause we are going to keep you up to date on everything going on with these ownership models on the vehicle. Two Point Oh podcast. Thanks for joining us. We hope you've enjoyed this deep dive. And if you have any questions. So first of all, we would love a five star rating over in your favorite podcast listener. And if you have any questions you'd go to our Facebook page over at spiffy a or I think through our vehicle 2.0 page. You can ask some questions, be happy to answer those. Thanks. And happy driving.

WPKN’s LGBTQ Community Radio Show and we are excited about this month’s show. We are speaking with Jay Blotcher about the new book “Rainbow Warrior: My Life in Color” Gilbert Baker...Creator of the Rainbow Flag”. Jay was tapped by the Gilbert Baker Estate to edit Gilbert’s various notes and 3 drafts for the project. Along with Charley Beal, Jay brought the colorful story of the amazing Gilbert Baker to life...so tune in to WPKN 89.5 this Wednesday at noon... As part of the current fundraising campaign the LGBTQ Community Radio Show has a copy of the book signed by Jay Blotcher, Charley Beal and the panel from the Stonewall Inn book presentation for a contribution of $100. Much thanks to the anonymous donor of the book and the Stonewall Inn panel Brendan Fay: A veteran LGBT activist, Fay was a co-founder of St. Pat's for All, the organization that defied the Ancient Order of Hibernians refusal to allow gays and lesbians to march in the annual St. Patrick’s Parade. The group finally achieved success in 2015. Fay is involved in countless LGBT and social justice groups, and is also a documentary filmmaker. Stacy Lentz: A world-renowned lesbian activist for LGBT rights, Lentz is a co-owner of the Stonewall Inn, and co-founder of the Stonewall Inn Gives Back Initiative. Lidell Jackson: A veteran activist in New York City’s LGBTQ community of color, Jackson was a member of the pioneering group Men of All Colors Together. He is an actor, dancer, and sexual liberationist, serving as founder and host of the long-running Jacks of Color social club. Cathy Marino-Thomas: has worked for same-sex marriage since 1998, serving as board president for Marriage Equality USA. She currently serves on the steering committee for Gays Against Guns. Her community advocacy began as a buddy for GMHC, helping people afflicted with HIV/AIDS.

Tim Gunn is known as the Emmy winning co-host and mentor for 16 seasons of Lifetime's cornerstone series "Project Runway," where he also served as one of the show's producers. He and co-host Heidi Klum won the 2013 Emmy Award for Outstanding Host for a Reality or Reality Competition Program, nabbing the award after his first nomination. 2017 marked the duo's fifth consecutive nomination in the category and the show has received thirteen consecutive nominations for Outstanding Reality Competition Program. In addition to his work on "Project Runway," Gunn also served as an Executive Producer, mentor and co-host of "Project Runway Junior" for two seasons. The show challenged young designer between 13-17 years old. In 2018, Gunn and Klum departed the beloved "Project Runway" for a brand-new venture with Amazon Studios. The pair will be seen globally as the pinnacle of the fashion world. Along with Gunn's television prowess, he is a recognized and sought after fashion executive and administrator. He served as Fashion Dean at Fifth & Pacific, where he was responsible for attracting, retaining and developing creative talent. Prior to his position at Fifth & Pacific, he was the Chief Creative Officer at Liz Claiborne Inc. Gunn served as a member of the administration and faculty at Parsons School of Design for 29 years and has a rich and deep history with the institution. In August 2000, Gunn was appointed Chair of the Department of Fashion Design at Parsons with the charge of retooling and invigorating the curriculum for the 21st century. Under his direction, the department was repositioned as the indisputable leader in fashion design education in America and as one of only a handful of leading programs in the world. Upon leaving Parsons, Gunn received the title of Honorary Chair of Fashion Design at the school. In addition, Liz Claiborne, Inc. endowed a scholarship in his name. Gunn is widely recognized as a leading expert in fashion and lifestyle design. His interviews have appeared in a wide range of publications including Newsweek, The New York Times, Entertainment Weekly, Esquire, Women's Wear Daily, Marie Claire, Fortune and Fast Company among others. He delivered the keynote address at Harvard Business School's Conference on Luxury Retail. He has also covered the red carpet at the Academy Awards, Emmy Awards and Golden Globes for "The Today Show" and "Entertainment Tonight," and he co-hosted the Official Oscar Red Carpet Pre-Show for ABC. Gunn is a well-known writer whose work has graced the New York Times Best Sellers list as author of Tim Gunn: A Guide to Quality, Taste and Style, Gunn's Golden Rules: Life's Little Lessons for Making It Work, and Tim Gunn's Fashion Bible: The Fascinating History of Everything in Your Closet. His most recent book, the critically acclaimed, Tim Gunn: The Natty Professor: A Master Class on Mentoring, Motivating, and Making it Work was released in March 2015. He has written articles for Elle, Seventeen, People, US Weekly and Fortune and had a monthly feature in People Style Watch and Marie Claire. The now 65 year-old was named one of People magazine's "Sexiest Men Alive." Marvel comics made him a superhero in their revival of Models, Inc. with a special feature, "Loaded Gunn," in which he dons the Iron Man armor to fight crimes against fashion. Currently, Gunn voices the character "Baileywick" on Disney Channel's hit animated series "Sofia the First." He has also made cameo appearances on the television shows "Ugly Betty," "How I Met Your Mother," "Drop Dead Diva" and "Gossip Girl" as well as the feature film "Sex and the City 2." Gunn devotes a good deal of his time to charitable organizations, especially those with a focus on domestic violence, AIDS awareness and GLBT issues. These organizations include the National Domestic Violence Hotline, GMHC, the Hetrick-Martin Institute and Bailey House. He resides in New York City. In this episode, Tim shares his one way ticket to his apartment. He also covers everything from where he buys his closes to Nancy Pelosi's style, from the "Slobification of America" to his love of fencing, from why he can't get off the Red Carpet fast enough to why he's all about risk taking, and more! Plus, he answers listeners' questions. Tim is just one of the dynamic guests featured on The One Way Ticket Show, where Host Steven Shalowitz explores with his guests where they would go if given a one way ticket, no coming back! Destinations may be in the past, present, future, real, imaginary or a state of mind. Steven's guests have included: Nobel Peace Prize Winner, President Jose Ramos-Horta; Legendary Talk Show Host, Dick Cavett; Law Professor, Alan Dershowitz; Broadcast Legend, Charles Osgood; International Rescue Committee President & CEO, David Miliband; Playwright, David Henry Hwang; Journalist-Humorist-Actor, Mo Rocca; SkyBridge Capital Founder & Co-Managing Partner, Anthony Scaramucci; Abercrombie & Kent Founder, Geoffrey Kent; Travel Expert, Pauline Frommer, as well as leading photographers, artists, chefs, writers, intellectuals and more.  

1980's art both personal and political arose out of the AIDS epidemic. Two major NYC art exhibits – Peter Hujar: Speed of Life (Morgan, thru May 20) and David Wojnarowicz: History Keeps Me Awake.   What do the lives of these masterful artists have to do with the art and activism of today?  Laura Flanders and her guests bring the exhibits together in a frank and probing discussion: David Kiehl, Joel Smith, artist Pamela Sneed-Visual Aids. Music: "Come On, Come On" Scott Hardkiss feat Lisa Shaw. Support theLFShow

Cecilia Gentili currently serves as the Director of Policy at GMHC, the world’s first and leading provider of HIV/AIDS prevention, care and advocacy. Originally from Argentina, Cecilia found her passion for advocacy and community service when she started working as an intern at the LGBT Community Center in New York City several years ago. Cecilia is also a contributor to Trans Bodies, Trans Selves: A Resource for the Transgender Community, and is a board member for Transcend Legal and Translatina Network. For fun, she loves performing at storytelling and stand-up comedy events where she talks about her life experiences. Cecilia is very passionate about advocating for her community, especially Latina transgender women who may have a history of sex work, drug use and incarceration.

In 1981 Larry Kramer sounded an alarm almost no one wanted to hear. Gay men were dying from a mysterious disease and the only way to stop its spread was to stop having sex. The outspoken activist went on to co-found GMHC and ACT UP, two of the leading organizations in the fight against AIDS. Visit our episode webpage for background information, archival photos, and other resources. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

In 1981 Larry Kramer sounded an alarm almost no one wanted to hear. Gay men were dying from a mysterious disease and the only way to stop its spread was to stop having sex. The outspoken activist went on to co-found GMHC and ACT UP, two of the leading organizations in the fight against AIDS. Visit our episode webpage for background information, archival photos, and other resources.

Chris Voparil, former president of Richard Rorty Society talks about his book the "Achieving our Country," and how Rorty had warned the Left of someone like Donald Trump rising to power. Eric Sawyer and Angel Soto of GMHC talk about being arrested and why we need to fight the repeal of ACA.

As a note, Alexander Charles Adams now uses they/them pronouns. This week, Alexander Charles Adams of SMASH/CUT joins me to discuss their piece, “Hi, I’m Mattie (HIM)”. Matthew Cavan is an actor and drag queen in Belfast, Northern Ireland; they came out about their HIV-positive status in 2010, and has since faced a torrent of criticism, shaming, and even death threats. The piece we’re playing today, “Hi, I’m Mattie”, is a verbatim piece -- that is, the script is taken word-for-word from interactions that Mattie had on the gay dating app Grindr, where they disclose their HIV-positive status up-front.Afterwards, Alexander (the producer of the piece) joins me to talk about the origins of SMASH/CUT, and many other things besides!Check out their new kickstarter, here:https://www.kickstarter.com/projects/adamsintheatre/847488277?token=3b1a1021Take the Wondery Survey here:http://www.wondery.com/surveyIf you feel moved to donate to HIV/AIDS-related causes, check out the GMHC: http://www.gmhc.org/

there are more unreached today than there were last year when we met at GMHC. 21 million more to be precise. We are going backwards in our task to complete the great commission and that is not OK. Meanwhile our traditional missions model has sidelined over 99% of Jesus followers who look at the model and do not see a fit. Yet God has made everyone for His purposes and uniquely talented them to fulfill the purposes. Those who are talented in the medical profession, who are passionate about it and believe they were created to do it have been told they have to leave that and do something different, (oh and raise support to do it) or simply do it on a short term mission trip or even as someone told me last year at GMHC, 'forget your specialty and come do general health care'. We will continue to go backwards unless we engage the whole body of Christ and engage them wholly. In other words send them out to be who God has created them to be. As GP's, Surgeons, Radiologists, Dentists, Pediatricians, Nurses..... what ever God has uniquely made them to do. The world is changing, the missions model has to change. Come hear how we are changing the face of mission and how you, as a medical professional can be at the cutting edge of that - but be warned our call to you is to be who God has made you to be, where He is not worshipped. This is session is for those who are truly interested in using all of their life to reflect God's glory and goodness.

Dr. Ralph Winter, founder of the US Center for World Mission and Perspectives… said that for every 100 people who made a mission commitment at some point in their lives, only one made it to the mission field. Why? For lack of mobilizers! The same can be said for lack of mentors. What is a mentor? What do mentors offer prospective long-term medical missionaries? Come to this session if you desire a mentor or if you desire to become a mentor. Before the session you may want to familiarize yourself with GMHC’s mentoring service at https://www.medicalmissions.com/community/mentoring . John McVay and I will walk you though this process. This session strives to translate your dreams of serving as a long-term medical missionary into reality.

This session will share answers on how to select a missions agency. Each person who attends will receive a 3 x 5 card when they enter the room. The moderator John McVay will group and select questions, direct them to appropriate panelists, and receive questions from the floor. Probable topics discussed from questions expected are: agency focus, doctrine, finances, services, leadership, locations, compatibility.   About the moderator:  John McVay is a missions mobilizer who organizes and moderates a panel of doctors and nurses at GMHC. For prospective missionaries in the USA John launched the Ask A Missionary email newsletter (circulation 2,000) and website. He co-founded The Journey Deepens weekend retreats and served for nine years as a missions pastor. He, his wife Nicole and their children lived and served as missionaries in China for a semester and in France for a year. John now serves In His Image International as Chief Operating Officer for the Family Medicine Residency and missions outreaches. John has a M.S. in Electrical Engineering and a M.Div. in Theology and Missions.

More than 90 million adolescents and youth live in the Middle East today. Adolescents are a key population group representing a triple return of investment, yet they are uniquely neglected in the regional challenges they face. Today, adolescents in the Middle East confront significant health, development, education, employment and socio-economic challenges especially related to the protracted crisis. Region-specific factors greatly influence their health, development, choices, and provision of public health and clinical services. Over the past two decades, adolescent health issues increasingly made their way to national agendas in many regions of the world, yet it’s only a drop in a bucket. Adolescents are the population that benefited least from the epidemiologic transition. Why does the Middle East lag behind? What are United Nations Health Organizations doing to improve the health of a billion adolescents who live in the world and in particular in the Middle East? Why are we failing adolescents? Why do countries in the region have to care for adolescents, their potential backbone for a vibrant future? How can governments and leading medical institutions ensure gender sensitive comprehensive health and development agenda for adolescents living in the Middle East? What can a GMHC participant do to help?

Mike Ruiz is a world-renowned photographer, creative director and director. Mike was born and raised in Montreal, Canada, and at the ripe age of 20, he moved to the United States with just $300 bucks in his pocket and a desire to be in the entertainment world. After working for more than a decade as a successful model, his true calling came into focus one Christmas morning, when he received a gift of a lifetime: his first camera. Wide-eyed, he took the camera out of the box, and in the blink of an adept eye, his whole life was about to change. With focused determination, Mike immediately took to his new present–taught himself the intricate mechanics of the camera and to this day, he hasn’t stopped clicking away. Perhaps it’s only when you might hear him say, “we got it!”, that there is but the slightest of pauses to an otherwise very hectic shooting schedule. Sharing with the world the images that he captures is tantamount to poetry. Whether it’s Kim Kardashian, Betty White, Nicki Minaj, Katy Perry or Prince, Mike has seen and shot them all.Like everything he touches, Mike is a man who brings to life the fantastical, which in turn, is inspired by his brilliant optimism. His lens has done a lot of zooming in and out, while the world keeps a keen focus on his high-impact, surreal brand of celebrity and fashion photography. He has successfully branded himself across platforms, including print and video, which expands his appeal in the industry. His clients include L’Oreal, Garnier, Jafra and AlfaParf. Mike’s work has appeared in Conde Nast Traveller, Elle, Interview, Paper, Flaunt, Spanish & Brazilian Vogue, Citizen K, Vanity Fair, Verve, and other publications. He is also a regular contributor to the following magazines: YRB (USA), Rouge (Russia), Prestige (Hong Kong), Spot (Mexico).Throughout it all, Mike’s hard work, dedication, and passion behind the camera gives him the opportunity to bring his message of hope to the forefront of all his efforts. Mike has a true sense of social responsibility and is always intent on giving back to the community. Among the countless organizations he supports, are GMHC, The Trevor Project, Housing Works, It Gets Better Campaign, Live Out Loud, Project Angel Food, GLAAD, and he is on the honorary board of the “Let There Be Hope” research foundation. Mike is also the communications consultant on The Men’s Sexual Health Project 36:00:00 for NYU School of Medicine, as well as a recurring motivational speaker at New York University, The Harvey Milk School, Art Center College of Design, Brooklyn International High School and the College of Design in Sacramento. Mike was recently awarded a Proclamation from the City of New York for his contribution to the arts and his philanthropic effort. His efforts extend to our 4 legged friends as well. Mike has become an advocate the protection and adoption of abused and abandoned pitbulls working closely with Los Angeles rescue, Bullies and Buddies.In addition to his photography and humanitarian work, Mike Ruiz has branched out as a director and television personality. He has produced music videos for artists, such as Vanessa Williams, Kelly Rowland, Jody Watley, Kristine W., Shontelle, The Blonds among others. Back in 2007, Mike took on a passion project for himself when he directed one of his role models, RuPaul, in an indie film entitled, Starrbooty.Mike has recently launched an APP for the iPad, iPhone and Android devices which will be a digital interactive extension of his book, Pretty Masculine. Versions of the all will soon be available for the iPhone and Android devices. The online promotional video has won him a Telly Award.VISIT MIKE RUIZ WEBSITE: WWW.MIKERUIZ.COM

"...she has like her cheerleading jacket inside glass and kind of on an easel, and all kinds of pictures of her daughter, and a swing outside on the lawn that has a plaque on it..." Kathy Shorr started out in photography by photographing her children and being told they were pretty good photographs. From there she took a night class at the School of Visual Arts and was told by her professor that the photos were very good, and after making sure her professor wasn't just being nice, she enrolled full-time at SVA where she graduated with honors. Kathy has a streak of social activism in her. She has taught documentary photo to kids with behavioral issues in the public school system, and she has taught photo workshops at GMHC and The Fortune Society. The success of Kathy's work comes directly from how she immerses herself into what she is working on. Her latest project, SHOT, explores survivors of gun violence. You can see more of her work at the links below. Links Follow Kathy on Twitter @katshorr https://twitter.com/katshorr See the SHOT project at http://www.shotproject.org See more of Kathy's work at http://www.kathyshorr.com Host: Michael Chovan-Dalton Show opening with Patrice Helmar Visit www.thephotoshow.org Follow us on Twitter twitter.com/realphotoshow and on Instagram instagram.com/realphotoshow/ Like us on Facebook www.facebook.com/realphotoshow Music by @pataphysics-1 on Soundcloud

Philippians 1:29

GMHC 2015 Saturday morning plenary session

GMHC 2015 Friday night plenary session

GMHC 2015 Friday Morning plenary session

Howard Grossman is a board-certified internist, who had a private practice in Manhattan from 1988 to 2005, which he reestablished in 2009. In 2013 he opened the only primary care private practice dedicated to LGBT health and HIV care in the state of New Jersey. He is a general internist, but is most widely known as a specialist in HIV medicine and LGBT Health. Dr. Grossman is a Senior Attending in the Department of Medicine at St. Luke’s-Roosevelt Hospital and is an Assistant Clinical Professor of Medicine at Columbia University, College of Physicians and Surgeons. He is Clinical Assistant Professor of Medicine at NYU-Langone Medical Center and an Attending Physician at Overlook Hospital in Summit, NJ, part of the Atlantic Health System.Dr. Grossman left private medical practice in 2004 to serve as the Executive Director of the American Academy of HIV Medicine, a professional association of 2100 front-line HIV providers, based in Washington, DC and held this position until 2006. In 2007 he served as the Medical Director of the Conant Medical Foundation in San Francisco, an organization dedicated to education and care as a way to fight the HIV epidemic. In that role he had both clinical and administrative functions. From 2008-2009 Dr. Grossman was part of the amazing team at Fenway Community Health in Boston, where he served as a staff clinician and as Associate Director for Industry-Sponsored Trials.In the interim between leaving AAHIVM and joining the Conant Medical Foundation Dr. Grossman worked as an international clinical mentor. He educated doctors and nurses in Russia and Belarus working with the American International Healthcare Alliance and he spent seven weeks in the Far West of Nepal helping to establish the first HIV treatment facility in this area with a high rate of HIV infection among migrant workers. This was a collaborative program between the International Center for Equal Healthcare Access (ICEHA) and Family Health International.Dr. Grossman earned a B.A. in political science at Haverford College and studied medicine at SUNY Downstate College of Medicine in Brooklyn. He did his residency at Kings County Hospital, one of the largest public hospitals in Brooklyn. It was there that he saw some of the first cases of AIDS in the early 1980’s.Dr. Grossman worked at St. Clare’s Hospital, at the first dedicated AIDS unit in the country and entered private practice in 1987. He has one of the largest HIV practices in New York and serves a diverse patient population. He has become nationally recognized as an educator on HIV issues and as an advocate for gay and lesbian civil rights and the rights of People with HIV.His work with people affected by HIV led him to become one of the plaintiffs in the landmark suit Vacco v. Quill, et al., which sought to overturn laws preventing terminally-ill patients from obtaining their physicians’ help to end their own lives. The case was decided in 1997, with the Supreme Court finding no constitutional guarantee of the “right to die,” but leaving the door open for states to experiment with various options.Dr. Grossman has written articles for many publications and for The Body.com. He has reviewed articles for The AIDS Reader and served as medical editor for columns in HX, POZ, GMHC’s Treatment Issues, AMFAR’s treatment newsletter among others.Dr. Grossman has served in the past as a consultant to many pharmaceutical companies, including Pfizer, Tibotec, Merck, GlaxoSmithKline, Abbott, Hoffman-LaRoche, Ortho Biotech, Janssen, Agouron, Gilead, Chiron, Monogram Biosciences, and Bristol-Myers Squibb. He has also worked with government panels at the National Institutes of Health and the Food and Drug Administration and served as a reviewer for CDC grant applications. Dr. Grossman was the medical advisor for the patient-oriented website www.aidsmeds.com. He has been involved with multiple community-based organizations. Most recently Dr. Grossman has served as Chair of Physicians for Compassionate Care, an organization of over 600 physicians in New York State who support the medical use of marijuana. Prior to taking the reins at AAHIVM he served as the Board chair for the New York State Chapter, and worked as the chairman of the Public Policy Committee and Chairman of the Ethics Committee. He has also served on the Board of Directors of several other organizations. He most recently served on the board of Bailey House, which provides housing and case management services for homeless people living with HIV and their families. In the past he has been on the boards of Visual AIDS, working with artists with HIV and using art to educate about HIV; the New York Chapter of Compassion in Dying, a national group dedicated to helping patients with end-of-life issues, especially around pain control; the Organization of HIV Healthcare Providers, a PAC organized to work on various issues of interest to people with HIV and their practitioners; and the honorary board of Love Heals/The Allison Gertz Foundation. Dr. Grossman also served on the boards of the Gay Men’s Health Crisis and the People with AIDS Health Group in the past. He organized and ran the medical tent for the GMHC Morning Party on Fire Island for 9 years, providing one of the first organized medical operations to serve a large party of this kind and helping to promote harm reduction and HIV prevention in this setting. He has been involved with a number of activist groups including ACT-Up, TAG, the Coalition for Salvage Therapy (CST) and the AIDS Treatment Activists’ Coalition (ATAC).You can find more info about Howard A. Grossman, MD  practice at www.alphabettercare.com.There are some writings Howard A. Grossman, MD has done for thebody.com on PrEP -Do HIV-Negative Gay Men Need Condoms if They're on PrEP? Here's What I Tell My PatientsI'm an HIV Physician. And I'm Starting PrEP.

During the main GMHC conference 2015 PRIME International's CEO, Prof Richard Vincent, presented this breakout session on ‘Compassion: Foundation for Whole Person Care’.Scientific and technical advances may be seen as the key to best medical practice, but to focus only on biological processes is to ignore other powerful influences on the causes and treatment of illness. A solely mechanistic approach fails to deal with the basic requirement of patients to be cared for as people - in body, mind and spirit. This session explored the topic of whole person care including its biblical basis, evidence for its benefit and its delivery to patients founded on compassion.

Dr. Ralph Winter said that for every 100 people who made a mission commitment at some point in their lives, only one made it to the mission field. Why? For lack of mobilizers! The same can be said for lack of mentors. What is a mentor? What do mentors offer prospective long-term medical missionaries? Come to this session if you desire a mentor or if you desire to become a mentor. Before the session you may want to familiarize yourself with GMHC’s mentoring service at https://www.medicalmissions.com/community/mentoring . This session strives to honor God by helping you translate your dreams of serving as a long-term medical missionary into reality.

Tonight Tex and Jason talk to Mike Williams, President of the VAC/GMHC about where the organisation is at and where he sees us in the future.

Tonight Adam and Jason are chatting with former exectutive director of the VAC/GMHC Mike Kennedy about the naughties.

Joining Tex and Jason tonight is Gordon Wilson, a long time volunteer with the VAC/GMHC, Tonight they are chatting about the 1990's

Jill and Tex tonight are starting 4 special shows for July that celebrate the 30th Anniversary of the VAC/GMHC. This show Ian Foote is chatting about the 1980's , the year the organisation was formed out of the  community by community members.

For over 20 years, David has served as the Principal and Founder of his New York based design firm, David Scott Interiors, LTD. He designs visually stimulating, yet highly functional interiors that gracefully meld practical architecture with unique design. His style blends the timeless elegance of the past with the verve of the present, using a collaborative and detail-oriented approach to create calming and beautiful environments. David's signature designs emphasize the personal style of his clients. The very fabric of his business lies in embracing the natural connection his clients have to their project, ensuring their personality and character are reflected in their interiors. The result is an inviting environment that is highly personal, comfortable, and practical. David Scott Interiors' projects have appeared in publications including Architectural Digest, The New York Times, The Wall Street Journal, House Beautiful, Gotham, The New York Observer, Interior Design, New York Spaces, Hamptons Magazine, Hamptons Cottages & Gardens, and HGTV.com. The firm has participated in many prestigious show houses and events to benefit charities including the Kips Bay Boys and Girls Club, the Breast Cancer Research Foundation, Southampton Hospital, Lenox Hill Neighborhood House, the New York Botanical Garden, and GMHC. In May 2013, David's first book, David Scott: Outside the Box, was published by Pointed Leaf Press. A delightful behind the scenes look into eleven of his most stunning projects, Outside the Box showcases the elements of inspiration that have been the guiding force for David's innovative and striking spaces, where comfort and chic harmoniously co-exist. An alum of the prestigious New York School of Interior Design and currently serving on its Board of Trustees, David resides in Manhattan and Water Mill, NY. When he's not designing, David enjoys entertaining friends, feeding his passion for art and antiques, and spending time with his two miniature Dachshunds, Ethan and Josie.

Tonight Adam and Tex will be chatting to David Eckel about his work in the area of D&A .

We will be discussing GMHC "I Love My Boo" Campaign with spokes persons Derrick L. Briggs & Jaszi Alejandro